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Development of Methods for Protein Delivery and the Directed Evolution of Recombinases 
Abstract 
As a class, protein-based therapeutics offer tremendous advantages over traditional small 
molecule drugs.  Due to their sizes and folding energies, proteins are ideal for catalyzing 
chemical reactions, and can bind tightly and selectively to extended target surfaces. However, 
due to their large size, virtually all proteins are unable to spontaneously enter cells, and as a 
result protein therapeutics are restricted to extracellular targets.  We developed a platform for 
delivery of proteins to intracellular target sites by engineering the surface chemistry of a model 
protein, green fluorescent protein (GFP).  We found that ‘supercharged’ cationic GFP variants 
(scGFPs) bind to anionic cell surface molecules and initiate endocytosis, resulting in the efficient 
delivery of translationally fused cargo to intracellular targets.  We discovered that scGFPs, and 
cationic delivery reagents in general, alter endosomal trafficking in a manner proportional to 
both their charge and their delivery efficiency, suggesting that avoidance of endosomal 
maturation is a key step in the endosomal escape of delivered protein cargos.  We also developed 
a method for encapsulation of recombinant proteins by cationic lipid delivery reagents using 
negatively supercharged GFP. 
Genetic modification technologies have matured rapidly following the discovery of 
protein classes with programmable DNA-binding specificities.  While site-directed genetic 
knockout technologies are highly effective, targeted integration and repair remain comparatively 
inefficient.  Site-specific recombinases directly catalyze strand exchange and ligation between 
DNA molecules, offering an approach to efficient genomic integration.  However, most site-iv 
 
specific recombinases are not easily reprogrammable.  To address this problem, we developed a 
genetic selection technique based on the Phage-Assisted Continuous Evolution (PACE) system, 
to enable the rapid evolution of recombinase proteins towards targets of interest.  Using Cre 
recombinase as a model, the PACE system was optimized, validated, and used to evolve Cre 
variants with higher activity on their native loxP target site, as well as altered specificity towards 
a human genomic sequence within the hROSA26 locus. 
Finally, we developed a method for enhancing the specificity of RNA-guided nucleases 
by restricting activity to sites of obligate dimeric nuclease assembly.  We engineered a FokI 
nuclease fusion to a catalytically inactivated Cas9 protein that mediates efficient modification 
with significantly reduced off-target activity. 
 v 
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Abstract 
  The inability of proteins to potently penetrate mammalian cells limits their usefulness as 
tools and therapeutics.  When fused to superpositively charged GFP, proteins rapidly (within 
minutes) entered five different types of mammalian cells with up to ~100-fold greater potency 
than corresponding fusions with known protein transduction domains (PTDs) including Tat, 
oligoarginine, and penetratin.  Ubiquitin-fused supercharged GFP when incubated with human 
cells was partially deubiquitinated, suggesting that proteins delivered with supercharged GFP can 
access the cytosol.  Likewise, supercharged GFP delivered functional, non-endosomal 
recombinase enzyme with greater efficiencies than PTDs in vitro, and also delivered functional 
recombinase enzyme to the retinas of mice when injected in vivo. 
Introduction 
  Proteins have demonstrated great value as research tools and as human therapeutics.  Due 
to the inability of virtually all proteins to spontaneously enter cells, however, exogenous proteins 
are predominantly restricted to interaction with extracellular targets and targets accessible 
through the endocytic pathway.  Over the past decade, a variety of reagents for the delivery of 
proteins into mammalian cells have been developed including lipid-linked compounds,1 
nanoparticles,2 and fusions to receptor ligands.3, 4   Perhaps the most commonly used method for 
protein delivery is genetic fusion to PTDs including the HIV-1 transactivator of transcription 
(Tat) peptide, oligoarginine, and the Drosophila Antennapedia-derived penetratin peptide.5, 6  
Despite these advances, intracellular targets remain difficult to perturb using exogenous proteins; 
even modest success can require high concentrations of exogenous protein due to the modest 
potency of most current methods.  Challenges for protein delivery are significantly increased in 
vivo, where cells in the context of a live animal have proven especially difficult targets for 3 
 
functional protein delivery.7, 8  The development of more potent protein transduction platforms 
would therefore significantly increase the scope of potential applications for protein reagents and 
therapeutics.  
We recently described “supercharged” GFP variants that have been extensively mutated 
at their surface-exposed residues, resulting in extremely high theoretical net charge magnitudes 
ranging from –30 to +48 (Figure 1.1).9  We discovered that superpositively charged GFP variants 
can enter a variety of mammalian cells by binding to anionic cell-surface proteoglycans and 
undergoing endocytosis in an energy-dependent and clathrin-independent fashion.10  Further, we 
observed that superpositive GFPs are able to form stable non-covalent complexes with nucleic 
acids and that +36 GFP can deliver siRNA and plasmid DNA into a variety of mammalian cell 
lines without apparent cytotoxicity.  
 
Figure 1.1 Electrostatic surface potentials of supercharged GFPs. -30 GFP, stGFP (the starting, non-
supercharged form of GFP, +36 GFP, and +48 GFP colored from -25kT/e (red) to +25kT/e (blue). 
 
Results 
  We hypothesized that +36 GFP may also serve as a potent and general platform for the 
delivery of proteins into mammalian cells.  We began by generating a variety of fusion proteins 
with +36 GFP, including the Tat peptide tag, ubiquitin, mCherry, and Cre recombinase. We 
observed that each fusion retained the fluorescence excitation and emission spectra of the 
unfused GFP (Figure 1.2), enabling measurement of their cell penetration by detection of cellular 4 
 
fluorescence.  The purified fusion proteins maintain the ability to rapidly (within 15 min) and 
potently (at low nM concentrations) penetrate mammalian cells (Figure 1.3) with low toxicity at 
doses in the low micromolar range (Figure 1.4). 
 
Figure 1.2 Characterization of +36 GFP fusion proteins. (a) Absorbance and (b) emission spectra of 
GFP fusion proteins shows equal fluorescence except for +36 GFP mCherry which shows reduced 
fluorescence at 515 nm and also an extra emission peak at 615 nm, presumably due to FRET with the 
attached mCherry fluorophore. 
 
Figure 1.3 +36 GFP protein fusions penetrate cells rapidly and potently. (a) Flow cytometry of HeLa 
cells incubated at the concentrations shown in the presence of +36 GFP fusions for 4 hours at 37° C. Cells 
were washed three times with 20 U/mL heparin in PBS to remove membrane bound protein prior to 
analysis. Untreated cells resulted in median GFP fluorescence values of 107 ±5. Error bars represent the 
standard deviation of three independent biological replicates. (b) Flow cytometry of HeLa cells incubated 
in the presence of 100 nM of each +36 GFP fusion at 37° C for the specified time. Untreated cells resulted 
in median GFP fluorescence values of 100 ± 6. Error bars represent the standard deviation of three 
independent biological replicates. 5 
 
 
Figure 1.4 +36 GFP and +36 GFP fusions are not toxic at concentrations effective for protein 
delivery.  At concentrations ≥ ~10 to 100 times the effective concentration for protein delivery in this 
work, +36 GFP-Cre (but not other +36 GFP fusion proteins or +36 GFP itself) reduced the viability of 
some cell lines and possibly stimulated IMCD cells. Values and error bars represent the average of and 
standard deviation, respectively, of three independent biological replicates. 
 
  Next we directly compared the ability of +36-GFP, Tat, Arg10, and penetratin to deliver 
fused mCherry,11 a red fluorescent protein variant.  We generated +36 GFP-mCherry, Tat-
mCherry, Arg10 -mCherry, and penetratin-mCherry with identical linkers and fusion orientations 
and found that their fluorescence properties were remarkably similar, enabling direct comparison 
of cell penetration between fusion proteins (Figure 1.5).  We incubated these four fusion proteins 6 
 
with HeLa cells, baby hamster kidney cells (BSR cells, a clone of BHK-21 cell line), NIH 3T3 
cells, inner medullary collecting duct (IMCD) cells, and rat pheochromocytoma PC12 cells in 
serum-free media at various concentrations for 4 h at 37 °C.   
 
Figure 1.5 Characterization of mCherry fusion proteins. Analysis of mCherry fusions to Tat, Arg10, 
and penetratin by (a) absorbance from 400 nm to 700 nm, and (b) emission spectra at 587 nm excitation. 
 
  After incubation, cells were washed under conditions confirmed to remove surface-bound 
protein (Figure 1.6), trypsinized, and assayed for internalized mCherry by flow cytometry 
(Figure 1.7).  For all five cell lines and at all concentrations tested (10 nM to 2 µM), +36 GFP 
delivered ~10- to 100-fold more mCherry than Tat or Arg10.  At concentrations ≤ 100 nM, +36 
GFP also delivered ~6- to 20-fold more mCherry than penetratin, which approached the potency 
of +36 GFP only in HeLa cells and only at the highest tested concentrations (1 M and 2 M).  
These results suggest that +36 GFP is a significantly more potent protein transduction agent than 
the widely used Tat, Arg10, and penetratin, especially at sub-micromolar concentrations.  
Delivery of mCherry into cells by +36 GFP was confirmed by live-cell confocal fluorescence  7 
 
 
Figure 1.6 Membrane-bound protein is removed by heparin washing conditions. (a) Livecell 
fluorescence microscopy indicates that at 4 °C +36 GFP-mCherry is membrane-bound but not 
internalized. After washing with heparin (but not after washing with PBS), this +36 GFP-mCherry 
signal is largely removed. At 37 °C, most of +36 GFP-mCherry signal remains even after heparin 
washing, consistent with internalization of +36 GFP-mCherry. (b) HeLa and PC12 cells subjected to 
the conditions described in (a) were trypsinized (which destroys surface-bound mCherry) then 
analyzed by flow cytometry. Cells incubated with +36 GFP-mCherry at 4 °C do not show significant 
mCherry fluorescence compared to cells incubated at 37 °C, further suggesting that the signal at 37 °C 
represents internalized protein signal, and that internalization at 4 °C is inefficient. 8 
 
 
Figure 1.7  Comparison of mCherry delivery by +36 GFP, Tat, Arg10, and penetratin.  (a) Flow 
cytometry of HeLa, BSR, 3T3, PC12 and IMCD cells incubated in the presence of the specified 
concentrations of +36 GFP-mCherry, Tat-mCherry, Arg10-mCherry, penetratin-mCherry or wild-type 
mCherry alone for 4 h at 37 °C.  Cells were washed three times with 20 U/mL heparin in PBS to remove 
membrane-bound protein before analysis.  Error bars represent the standard error of three independent 
biological replicates.  (b) Confocal fluorescence microscopy of live cells incubated with 100 nM +36 
GFP-mCherry for 4 h at 37 °C.  Red color represents mCherry signal; green color represents +36 GFP 
signal.  The scale bar is 15 µm.  
 
microscopy (Figure 1.7b) and by comparison with control experiments in which endocytosis was 
blocked at 4˚C and protein remains surface-bound (Figure 1.6).   
  To study the ability of proteins delivered with +36 GFP to access the cytosol, we 
generated a ubiquitin-+36 GFP fusion in which the C-terminus of ubiquitin was directly followed 
by +36 GFP.  A direct fusion of this type is recognized and processed by cytosolic 
deubiquitinases (DUBs), and DUB-dependent deubiquitination has previously been used as an 
indicator of cytosolic exposure.12, 13  A mutant form of ubiquitin (G76V) that is not a substrate 9 
 
for DUBs12 was similarly fused to +36 GFP to distinguish the effect of cytosolic DUBs from 
non-specific proteolysis.   
 
Figure 1.8  Deubiquitination suggests cytosolic exposure of a ubiquitin-+36 GFP fusion protein.  (a) 
Western blots using anti-GFP antibodies.  Lanes 1-3: purified protein samples of +36 GFP, wild-type 
ubiquitin–+36 GFP fusion (wt) or G76V mutant ubiquitin–+36 GFP fusion (mut).  Lanes 4 and 5: purified 
protein spiked into HeLa cell lysate to confirm that lysis conditions do not affect fusion protein integrity.  
Lanes 6-11: the indicated cells were treated with 100 nM of either the wt or mutant ubiquitin–+36 GFP 
for 1 h, then lysed.  (b) Mean extent of deubiquitination of wt ubiquitin–+36 GFP fusion protein in HeLa, 
3T3, and BSR cells.  Error bars reflect the standard deviation of three independent biological replicates.  
(c) In vitro deubiquitination control experiment.  Ubiquitin–+36 GFP fusion proteins were incubated in 
either HeLa cytosolic extract or in HeLa cytosolic extract containing one of two DUB inhibitors, 10 mM 
N-ethylmaleimide (NEM) or 20 µg/mL ubiquitin-aldehyde (Ub-Al) for 1 h at 37 °C.  
 
  After a 1 h incubation of HeLa cells, 3T3, or BSR cells with either 100 nM ubiquitin-+36 
GFP or 100 nM ubiquitin G76V +36 GFP, a significant fraction (HeLa: 25 ± 5.8%; 3T3: 27 ± 
2.4%; BSR: 24 ± 4.0%) of internalized +36 GFP was deubiquitinated, producing a protein equal 
in size to +36 GFP (Figure 1.8a, b).  In contrast, in all cases the G76V mutant-+36 GFP fusion 10 
 
was not appreciably cleaved, indicating that this reduction in size does not arise from non-
specific endosomal proteases but instead from the action of DUBs.  Ubiquitin-+36 GFP spiked 
into the cell lysis buffer prior to harvesting untreated cells was not cleaved (Figure 1.8a), 
indicating that the observed deubiquitination is a result of exposure to cytosolic DUBs, and not 
due to contact with DUBs during the cell-harvesting procedure.  Additionally, ubiquitin-+36 
GFP was completely deubiquitinated when incubated in HeLa cytosolic extract for 1 h, while the 
DUB inhibitors N-ethylmaleimide14 and ubiquitin-aldehyde15 blocked deubiquitination (Figure 
1.8c), further suggesting that the cleavage of ubiquitin-+36 GFP is a result of DUB activity.  
Collectively, these results demonstrate that some of the ubiquitin-+36 GFP protein fusion can 
access cytosolic enzymes in three distinct mammalian cell lines. 
  Next we compared the ability of +36 GFP, Tat, Arg10, and penetratin to deliver a 
functional enzyme, Cre recombinase, into a variety of mammalian cells.  Exogenously delivered 
Cre must escape the endosome, localize to the nucleus, and tetramerize to mediate DNA 
recombination.16  We generated +36 GFP-Cre, Tat-Cre, Arg10-Cre, and penetratin-Cre fusion 
proteins and tested their ability to effect recombination in HeLa cells transiently transfected with 
pCALNL-DsRed2,17 a DsRed2-based Cre activity reporter plasmid.  After incubation with 100-
1000 nM of each Cre fusion protein for 4 h in serum-free media, cells were washed to remove 
surface bound protein and incubated in full media for 48 h.  Delivery of Cre was assayed by 
following DsRed2 expression using flow cytometry and fluorescence microscopy (Figure 1.9a).  
We observed that +36 GFP-Cre generated ~2- to 5-fold more recombinants than the 
corresponding fusions with Tat, Arg10, or penetratin. 
  Cre delivery was further evaluated in a NIH-3T3 cell line harboring an integrated lacZ-
based Cre-reporter5.  After incubation, treatment, and washing as described above, these cells 11 
 
were stained with X-Gal to identify recombinants.  Consistent with the HeLa cell results, +36 
GFP-Cre resulted in more efficient generation of recombinants than Tat, Arg10, or penetratin.  
The efficacy of +36 GFP-Cre was 10 to 100-fold higher than that of the other Cre fusions at 100 
nM, 10-fold higher at 500 nM, and 5-fold more at 1 µM (Figure 1.9b).  These findings together 
indicate that +36 GFP can deliver substantially more functional Cre than Tat, Arg10, or penetratin 
in these cell lines. 
 
Figure 1.9 Delivery of active Cre recombinase into mammalian cells in vitro.  (a)  Cre-mediated 
recombination in HeLa cells transiently transfected with pCALNL-DsRed2 and treated with +36 GFP-
Cre, Tat-Cre, Arg10-Cre, or penetratin-Cre for 4 h at 37 °C.  The image is an overlay of DsRed2 signal 
and brightfield images of HeLa cells transfected with pCALNL-DsRed2 and treated with 100 nM +36 
GFP–Cre.  (b) Cre-mediated recombination in 3T3.LNL.LacZ cells treated with +36 GFP-Cre, Tat-Cre, 
Arg10-Cre, or penetratin-Cre for 4 h at 37 °C.  The image is of 3T3.loxP.lacZ cells treated with 500 nM 
+36 GFP–Cre and stained with X-Gal.  (c) Cre-mediated recombination in BSR.LNL.tdTomato cells 
treated with +36 GFP-Cre, Tat-Cre, Arg10-Cre, or penetratin-Cre for 4 h at 37 °C.  The image is an 
overlay of tdTomato signal and brightfield images of BSR.LNL.tdTomato cells treated with 100 nM +36 
GFP–Cre.  (d) Identical to (c) but with the addition of 100 µM chloroquine during and after protein 
treatment.  In (a)-(d), error bars reflect the standard error of three independent biological replicates. 12 
 
  Next, we used BSR cells to generate a Cre reporter cell line conditionally expressing the 
tdTomato fluorescent protein after Cre-mediated DNA recombination.  Following treatment as 
described above, Cre-mediated recombination was quantified by flow cytometry.  In this cell 
line, +36 GFP was 2- to 15-fold more effective than Arg10 or penetratin (Figure 1.9c).  At low 
concentrations, +36 GFP delivered modestly higher levels of functional Cre than Tat, while 
higher concentrations Tat-Cre generated ~2-fold more recombinants than +36 GFP-Cre.  This 
cell line exhibits unusual features, including a high metabolic rate (doubling time = ~12 h18), that 
led us to speculate that endosomal trafficking to lysosomes may be unusually efficient in these 
BSR cells compared with HeLa- and 3T3-based reporter cells.  Indeed, when BSR cells were 
incubated with the Cre fusions in the presence of 100 µM chloroquine, an inhibitor of protein 
lysosomal degradation,19 we observed a dramatic increase in the number of recombinants arising 
from +36 GFP-Cre treatment and modest improvements for Tat-Cre, Arg10-Cre, and penetratin-
Cre, such that at all concentrations tested +36 GFP-Cre delivered more recombinase activity than 
any of the other proteins (Figure 1.9d).  These results suggest that the unique cell-penetration 
potency of +36 GFP can be more fully exploited by extending the time available for internalized 
protein to escape endosomes, resulting in even higher levels of delivered functional protein.  
Supporting this hypothesis, in vitro recombinase assays show that while +36 GFP-Cre is not 
active as the full length fusion, at pH 5.5-6.5 cathepsin B, a ubiquitous mammalian endosomal 
protease, will cleave +36 GFP-Cre to reveal +36 GFP and active Cre (Figure 1.10a).   At pH 5.0, 
the exopeptidase activity of cathepsin B is maximized 20, and we find no full length Cre 
remaining from the cleavage reaction nor do we observe recombinase activity in vitro (Figure 
1.10b, c ).  This is consistent with choloroquine’s mechanism for inhibiting lysosomal protein 
degradation, which is by preventing complete acidification of lysosomes21. 13 
 
 
Figure 1.10 Protease cleavage dependence of +36 GFP-Cre activity. (a) The concentration of Cre 
proteins was verified explicitly by in vitro activity assay. All Cre proteins showed roughly 50% cleavage 
activity at 300 femtomoles/reaction and nearly quantitative activity at 1000 femtomoles/reaction. Note 
that +36 GFP-Cre did not exhibit activity as the fusion protein but exhibited wild-type-like activity once 
cleaved by cathepsin B. Cleavage and activity of +36 GFP-Cre incubated with cathepsin B in buffer at 
various pH values. (b) Western blot of +36 GFP-Cre incubated with or without cathepsin B. Incubation of 
50 picomoles of +36 GFP-Cre with or without 0.5 μg cathepsin B (Sigma) in 20 μL of 50 mM MES, pH 
5.0-6.5 at 37º C for 45 min results in variable amounts of full-length +36 GFP-Cre, Cre, and +36 GFP. 
Note that at pH 5.0, Cre is largely degraded by cathepsin B, while at higher pH values, Cre is cleaved 
from +36 GFP but is not degraded to a significant extent. (c) The in vitro recombinase activity of the 
products of +36 GFP-Cre incubation with cathepsin B at the pH values indicated demonstrate that +36 
GFP-Cre is not active as the full-length fusion or after incubation (degradation) with cathepsin B at pH 
5.0. The upper band is Cre substrate DNA, while the lower band is recombination product, as in (a). 14 
 
  Finally, we tested +36 GFP as a protein delivery agent in vivo.  First we examined the 
tissue penetration of +36 GFP in the adult mouse retina.  We injected 0.5 µL of 100 µM +36 
GFP into the subretinal space of CD1 adult mice.  After 6 h, the retinas were harvested and 
analyzed by fluorescence microscopy (Figure 1.11a).  Most of +36 GFP was observed by the 
photoreceptor outer segments, but significant signal was observed throughout the retina, 
including all three nuclear layers (the outer, inner, and ganglion cell layers) as well as in the cell 
processes.   
 
Figure 1.11 Delivery of active Cre recombinase into mouse retinal cells in vivo.  (a) Fluorescence 
microscopy of a retinal section of a CD1 adult mouse injected with 0.5 µL of 100 µM +36 GFP.  The 
retina was harvested and analyzed six h after injection.  GFP fluorescence is shown in green and DAPI 
nuclear stain is shown in blue.  (b) Retinal sections of neonatal RC::PFwe mouse pups harboring a 
nuclear LacZ reporter of Cre activity.  Three days after injection of 0.5 µL of 40 µM wild-type Cre, Tat-
Cre, or +36 GFP-Cre, retinae were harvested, fixed, and stained with X-gal.  (c) Dots on the graph 
represent the total number of recombined cells counted in each retina.  The horizontal bar represents the 
average number of recombined cells per retina for each protein injected (n = 4 for wild-type Cre, n = 6 for 
Tat-Cre, n = 6 for +36 GFP-Cre).  
 
   To test ability of +36 GFP to deliver functional protein in vivo, we injected +36 GFP-Cre 
into the subretinal space of RC::PFwe mouse p0 pups containing a LoxP-flanked transcriptional 15 
 
terminator upstream of a nuclear lacZ reporter gene.22  Three days after injection of 0.5 µL of 40 
µM wild-type Cre, Tat-Cre, or +36 GFP-Cre, retinae were harvested, fixed, and stained with X-
gal (Figure 1.11b).  Injection of +36 GFP-Cre generated an average of 715 recombined cells per 
injected retina (n = 6), Tat-Cre generated an average of 318 recombined cells (n = 6) while wild-
type Cre generated an average of 117 recombined cells per retina (n = 4) (Figure 1.11c).  To our 
knowledge, this is the first report of functional delivery of an enzyme into retinal cells in vivo. 
Discussion 
    Side-by-side comparisons of +36 GFP, Tat, Arg10 and penetratin fused to mCherry or Cre 
recombinase revealed that fusions with supercharged GFP result in dramatically higher levels of 
internalized protein (up to ~100-fold) and in significantly greater efficiencies of Cre-induced 
recombination (up to ~10-fold) than three currently used protein transduction domains in a 
variety of mammalian cell lines.  Functional Cre recombinase can also be delivered to cells upon 
injection in vivo using +36 GFP.  These results collectively demonstrate the potential of 
supercharged proteins as an unusually potent in vitro and in vivo protein delivery platform. 
Methods 
Live-Cell Imaging 
Cells were plated onto 35 mm glass-bottom microwell dishes with a No. 1.5 cover glass 
(MatTek) at a density of 106 cells per plate.  After 18 h, cells were washed once with cold PBS 
and incubated with protein in serum-free DMEM. After incubation, cells were washed three 
times with cold 20 U/mL heparin in PBS to remove membrane-bound protein, imaged in 
prewarmed HEPES imaging solution (1 mM MgCl2, 5 mM KCl, 5 mM CaCl2, 150 mM NaCl, 
1.9 g/L glucose, 1.9 g/L albumin, 20 mM HEPES, pH 7.4, 37 °C).  Cells were imaged on an 16 
 
Olympus IX71 spinning disk confocal microscope on a heated stage with a 100X objective lens.  
GFP and mCherry were visualized by with a 491 nm and 561 nm excitation laser, respectively.  
Images were prepared using OpenLab software. 
For live-cell images of Cre reporter cells, cells were treated with 500 nM +36 GFP-Cre as 
described below for analysis of Cre recombination and imaged on an Olympus IX51 fluorescent 
microscope with a DP30BW black and white camera.  Images are false-color overlays of the 
fluorescent signal on a bright-field image.  LacZ-positive cells were imaged on an IX70 
microscope under bright-field illumination with a DP70 camera. 
Flow Cytometry and mCherry Delivery Assays 
Cells were plated into a 48-well plate at a density of 5 x 105 cells per well.  After 18 h, 
cells were washed once with cold PBS and incubated with protein in serum-free DMEM. After 
incubation, cells were washed three times with cold 20 U/mL heparin in PBS to remove 
membrane-bound protein, trypsinized, resuspended in 500 µL of full media and placed on ice.  
Cells were analyzed on either a LSRII or Fortessa flow cytometer (BD Biosciences) for GFP 
internalization (ex: 488 nm) or mCherry internalization (ex: 561 nm).  Cells were gated for live 
cells and at least 5 x 104 live cells were analyzed for each treatment.  Data was analyzed with 
FlowJo software (Tree Star, Inc.) 
In Vitro Cre Delivery Assays 
  Hela cells were plated at 3 x 104 cells/well in 48-well plates.  After 16 h, cells were 
transfected with pCALNL-DsRed217 using Effectene transfection reagent (Qiagen).  After 
incubation with 100-1000 nM of each Cre fusion protein for 4 h in serum-free DMEM, cells 
were washed three times with 20 U/mL heparin in PBS and incubated in full media for 48 h.  17 
 
Delivery of Cre was assayed by following DsRed2 expression using flow cytometry and 
fluorescence microscopy. 
  Cre reporter 3T3 cells were plated at 1 x 105 cells/well in 48-well plates.  After 16 h, cells 
were incubated with various concentrations of protein for 4 h in serum-free media.  Cells were 
washed with three times with 20 U/mL heparin in PBS and incubated in full media for 48 h.  
Recombined cells were quantified by X-gal staining and manual counting. 
BSR cells were obtained from Matthias Schnell (Thomas Jefferson University).  A 
pQCXIX MMLV retrovirus (Clontech) containing the tdTomato cre reporter construct was 
generated by subcloning the tdTomato gene (Clontech) into a pCALNL backbone17 and 
packaged using Plat-E cells23.  BSR cells were infected with retrovirus and integrants were 
selected for one week in the presence of 1 mg/ml G418 (Sigma).  BSR.LNL.tdTomato cells were 
plated at 1 x 105 cells/well in 48 well plates.  After 16 h, cells were incubated with various 
concentrations of protein for 4 h in serum-free media.  Cells were washed with three times with 
20 U/mL heparin in PBS and incubated in full media for 48 h.   
For chloroquine treatment of BSR cells, cells were incubated with Cre fusion proteins for 
4 h in serum-free media containing 100 µM chloroquine, washed three times with 20 U/mL 
heparin in PBS, and incubated 12 h in full media containing 100 µM chloroquine.  Following 
this incubation, cells were washed once with PBS and incubated a further 36 h in full media 
without chloroquine.  Delivery of Cre was assayed by following tdTomato expression using flow 
cytometry and fluorescence microscopy. 
For fluorescent Cre reporters, recombinants were identified by flow cytometry as those 
cells of the live-cell population that exhibited significantly higher fluorescence than that of non-18 
 
treated reporter cells.  Typically, the recombined population exhibited fluorescence at least 10-
fold higher than the non-recombined cells and were readily detected as a distinct subpopulation.  
Fluorescence gates were drawn accordingly to quantitate recombined and non-recombined cells. 
In Vivo Cre Delivery 
RC::PFwe mice were obtained from Susan Dymecki (Harvard University).  All of the 
experiments in this study were approved by the Institutional Animal Care and Use Committee at 
Harvard University.   Adult CD1 mice were subretinally injected with 0.5 µL of 100 µM +36 
GFP.  After 6 h, the retinas were harvested and analyzed by fluorescence microscopy.  p0 pups 
were subretinally injected with 0.5 µL of 40 µM wtCre, Tat-Cre, or  +36 GFP-Cre.  After 72 h, 
retinae were harvested and fixed with 0.5% glutaraldehyde.  Fixed retinae were stained with X-
gal overnight and embedded in 50% OCT, 50% of 30% sucrose and stored at -80° C.  Retinae 
were cut into 30 µm sections and imaged for X-gal staining on a Zeiss Axiophot brightfield 
microscope with a Nikon CXM-1200F camera.  Delivery of Cre was assayed by manually 
counting LacZ+ cells.  
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Chapter 2: 
Cellular Uptake Mechanisms and Endosomal Trafficking of Supercharged Proteins and 
Liposomal Delivery of Anionic Supercharged Protein Fusions 
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Abstract 
Supercharged proteins can deliver functional macromolecules into the cytoplasm of 
mammalian cells with potencies that exceed those of cationic peptides.  The structural features of 
supercharged proteins that determine their delivery effectiveness and the intracellular fate of 
supercharged proteins once they enter cells have not yet been studied.  Using a large set of 
supercharged GFP (scGFP) variants, we found that the level of cellular uptake is sigmoidally 
related to net charge, and that scGFPs enter cells through multiple pathways including clathrin-
dependent endocytosis and macropinocytosis.  Supercharged proteins activate Rho and ERK1/2, 
and also alter the endocytic transport of transferrin and EGF.  Finally, we discovered that the 
intracellular trafficking of endosomes containing scGFPs is altered in a manner that correlates 
with protein delivery potency.  Collectively, our findings establish basic structure-activity 
relationships of supercharged proteins and implicate the modulation of endosomal trafficking as 
a determinant of cell-penetration and macromolecule-delivery efficiency. 
 
Introduction 
The vast majority of nucleic acids and proteins encoded by the human genome are 
intracellular.  Molecular strategies to perturb the function of most biological targets for research 
or therapeutic purposes therefore require agents that can enter cells.  While membrane-permeable 
small molecules have dominated therapeutics over the past several decades, the use of 
macromolecules to address biomedical targets has more recently become a focus of intense 
research1, resulting in a number of macromolecular human drugs2.  Macromolecules can offer 
significant advantages over traditional small molecule-based therapeutics.  Macromolecules 
possess sizes and folding energies that are ideal for catalyzing chemical reactions, potently and 
selectively binding to extended target surface areas, and encoding gene products.  These key 23 
 
features, juxtaposed with the inability of virtually all macromolecules to spontaneously enter 
cells, create an urgent need to develop effective and general methods for the delivery of 
functional proteins and nucleic acids into mammalian cells3,4.   
While a host of protein delivery methods have been developed over the past decade— 
most notably those based on cationic cell-penetrating peptides (CPPs)5, 6, but also including 
antibodies7, receptor ligands8, nanoparticles9, and virus-like particles10 — these approaches have 
not achieved widespread use, and modestly successful protein delivery has historically required 
high doses of purified protein.   We recently developed a platform for macromolecule delivery in 
vitro and in vivo based on supercharged proteins (SCPs)11, 12, 13.  SCPs possess extremely high 
positive theoretical net charge at their surfaces and candidate SCPs can be generated 
computationally from native, non-supercharged proteins14.  Proteins can be mutated into SCPs 
without necessarily abolishing the protein’s native structural or functional properties14.  
Recently, we identified a class of naturally occurring supercharged human proteins with 
theoretical net charge:molecular weight ratios similar to those of engineered SCPs11.  These 
naturally occurring human SCPs exhibit similar potent cellular uptake and macromolecule-
delivery properties as engineered SCPs.  When compared to the most commonly used cell-
penetrating peptides (CPPs) and commercial nucleic acid delivery reagents, SCPs can result in 
more effective protein and nucleic acid delivery across a range of cell and tissue types in vitro 
and in vivo12,13,11. 
The molecular mechanisms by which SCPs enter and are trafficked in cells are largely 
unknown.  Previous studies suggest that cell entry of SCPs shares some mechanistic features 
with that of other cationic delivery reagents13, such as binding to sulfated proteoglycans to 
mediate initial cellular association, followed by endocytosis and some degree of endosomal 24 
 
escape to the cytosol.  However, SCPs can be more efficient at achieving both cell entry and 
functional macromolecule delivery to the cytosol than CPPs12,13.  It is not understood whether the 
high delivery potency of SCPs compared with CPPs results solely from the higher theoretical net 
charges attained by SCPs, or from the globular, structured nature of SCPs compared with much 
shorter and less structured peptide tags.  Observations that support the latter hypothesis include: 
(i) increasing the theoretical net charge of CPPs beyond approximately +15 typically does not 
increase, and eventually decreases, their cell penetration potency15; (ii) substitution of arginines 
on the surfaces of small proteins has been shown to endow these proteins with cell-penetrating 
abilities16 beyond those of similarly charged cationic peptides; (iii) the cell-penetration 
capabilities of oligoarginine peptides have been enhanced by the introduction of disulfide bonds 
that presumably stabilize the three-dimensional structure of the cationic peptide17; (iv) 
introducing spacer sequences between cationic residues throughout an oligoarginine peptide has 
also been shown to increase the effectiveness of cellular uptake18; (v) the distribution of cationic 
residues on the surface of proteins, and not merely charge magnitude, has been shown to alter the 
effectiveness of certain cell-penetrating proteins19.  Consistent with these findings, we have 
observed that SCPs exhibit more potent cell penetration and nucleic acid delivery abilities than 
synthetic peptides of similar or even greater positive theoretical net charge13.   
  In this work we investigate in detail the role of theoretical net charge and charge 
distribution on the cellular uptake and delivery properties of SCPs using supercharged GFP 
(scGFP) as a model.  We examined the extent to which SCPs and CPPs alter endocytic processes 
using a wide range of biochemical assays and high-throughput confocal microscopy.  We find 
that cellular uptake and delivery potencies are strongly charge-dependent, and that supercharged 
proteins outperform unstructured peptides of similar charge.  We further find that delivery 25 
 
potency correlates with the activation of specific cellular signaling markers, altered endocytosis, 
and subcellular trafficking.  These findings provide mechanistic insights into the unusual ability 
of supercharged proteins to enter cells and deliver macromolecules, and inform the future 
development and application of these agents. 
 
Results 
Previously we observed that the CPPs Tat, Arg10, and penetratin delivered protein into 
cells with up to 100-fold lower potencies than that of +36 GFP12, and that protein and nucleic 
acid delivery efficiencies mediated by three supercharged GFP variants (+15, +25, and +36 GFP) 
correlated with their theoretical net charge13.  These observations prompted us to characterize in 
detail (i) the relationship between net theoretical charge and cellular uptake potency, and (ii) the 
effect of charge distribution, either across the surface of a protein or within an unstructured 
peptide tag, on cellular uptake and delivery potency. 
To elucidate these relationships, we generated a collection of 28 scGFP variants with a 
wide range of theoretical net charges as well as different patterns of charge distribution (Figure 
2.1).  Genes encoding the variants were constructed by combining DNA fragments derived from 
the coding sequences of previously developed GFPs: stGFP (starting GFP, a non-supercharged 
variant), +15 GFP, +25 GFP, +36 GFP, and +48 GFP14.  Each resulting scGFP variant was 
expressed and purified from E. coli cells.  The absorbance and fluorescence emission spectra of 
all 28 scGFPs were very similar (Figure 2.2), enabling us to use fluorescence to directly 
compare the cellular uptake of these proteins.   
 
 26 
 
 
Figure 2.1 Electrostatic potential of the scGFPs.  PyMol renderings of each scGFP variant in the same 
spatial orientation.   The surfaces are colored from red (-) to blue (+) based on electrostatic potential to 
help visualize the difference between specific scGFP variants.  The original scGFPs used to elaborate the 
rest are labeled in bold green text.  The scale is in units of kbT. 
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Figure 2.2 The absorbance and fluorescence emission spectra of scGFPs.  2 M of each scGFP 
protein in PBS was loaded into a black clear-bottomed 96-well plate and scanned for absorbance (left) 
from 460 nm to 520 nm in 5 nm steps, and scanned for fluorescence emission with excitation at 470 nm 
from 495 nm to 570 nm in 5 nm steps (right). 
 
To determine the relationship of charge to cell uptake, each scGFP variant was incubated 
with HeLa cells for 4 hours across a range of concentrations.  Following incubation, cells were 
washed using conditions previously shown to remove excess non-internalized protein12,13,11, 
trypsinized, and assayed for protein uptake by flow cytometry.  For comparison, Tat-stGFP and a 
GFP engineered by Raines and coworkers to contain an arginine patch20 were also incubated 
with HeLa cells and processed in an identical manner.  The degree of cellular uptake was 
measured as the median cellular fluorescence of the population of cells.  The relationship of 
theoretical net charge to cellular uptake was found to be strongly sigmoidal, and consistent 28 
 
across doses ranging from 20 nM to 2 µM (Figure 2.3).  Low-potency uptake, comparable to 
that of Tat peptide, was observed among proteins with net theoretical charge < ~+20.    
 
Figure 2.3 The charge-uptake relationship of scGFPs is consistent across protein dosage.  HeLa cells 
treated with either 20 nM, 200 nM, or 2000 nM of each scGFP.  The scGFPs included are +6, +7, +9, 
+15, +20, +22, +23, +25, and +36 GFP.  Error bars represent the standard deviation of three independent 
replicates. 
 
In contrast, a high-potency regime exhibiting 100-fold higher cellular uptake potency was 
observed for highly charged proteins (Figure 2.4a).  For GFP, the inflection point between the 
low- and high-potency regimes occurs at a theoretical net charge of approximately +22 (Figure 
2.4a, green points), well above the net charge of CPPs.  As this net charge-to-cellular uptake  
relationship predicts, Tat-stGFP (+1 theoretical net charge) exhibited potency comparable to that 
of other modestly charged, low-potency charged GFP variants, including the Arg-grafted GFP20 
(Figure 2.4a).  The striking change in cell penetration effectiveness from low- to high-potency 
variants suggests that these variants may enter cells through the involvement of different cellular 
interactions or through distinct uptake pathways. 
 29 
 
 
 
0
50
100
150
200
250
+0 +10 +20 +30 +40 +50
f
o
l
d
 
ﬂ
u
o
r
e
s
c
e
n
c
e
 
o
v
e
r
 
u
n
t
r
e
a
t
e
d
theoretical net charge
A
0
50
100
150
200
250
+0 +10 +20 +30 +40 +50
f
o
l
d
 
ﬂ
u
o
r
e
s
c
e
n
c
e
 
o
v
e
r
 
u
n
t
r
e
a
t
e
d
theoretical net charge
B
0
50
100
150
200
250
300
350
0 500 1000 1500 2000
f
o
l
d
 
ﬂ
u
o
r
e
s
c
e
n
c
e
 
o
v
e
r
 
u
n
t
r
e
a
t
e
d
concentration (nM)
C
0.00
5.00
10.00
15.00
20.00
25.00
30.00
0 250 500 750 1000
%
 
r
e
c
o
m
b
i
n
a
n
t
 
c
e
l
l
s
concentration (nM)
D
0.00
10.00
20.00
30.00
40.00
50.00
60.00
70.00
80.00
90.00
0 500 1000
%
 
r
e
c
o
m
b
i
n
a
n
t
 
c
e
l
l
s
concentration (nM)
Tat
Arg10
penetratin
+9
+15
+24
+25
+25a
+25b
+35
+36
+37
+48
E
Arg10
Tat-stGFP
arginine-grafted GFP
original scGFPs
shufﬂed scGFPs
high charge density scGFPs
     
 
Figure 2.4  Charge dependence of cellular uptake supercharged GFPs.  (a) and (b) HeLa cells were 
treated with 200 nM of each purified scGFP protein for 4 hours, washed to remove surface-bound protein 
and analyzed by flow cytometry.  Plots show fold median GFP fluorescence intensity relative to untreated 
control cells.  Blue points represent scGFPs generated by shuffling stGFP, +15 GFP, +25 GFP, and +36 
GFP sequences.  Red points represent scGFPs generated by shuffling stGFP, +15 GFP, +25 GFP, +36 
GFP, and +48 GFP sequences to create proteins with less even charge density.  Green points represent 
starting +15, +25, +36, and +48 GFPs.  The grey point is Tat-stGFP, and the black point is an arginine-
grafted GFP. 
 
  To examine the effect of SCP charge distribution on cell penetration, we generated a 
series of scGFPs that alter charge distribution without varying theoretical net charge, which was 
maintained at approximately +25 and +36.   The variants within this series were constructed 
from segments of +48 GFP together with segments of +15 GFP and +25 GFP and therefore 
contained a more uneven cationic charge distribution than canonical +25 or +36 GFPs, with 
basic residues concentrated into more limited regions of the protein surface.  We observed 
significantly different levels of cellular uptake potencies among scGFPs with similar or identical 
theoretical net charges but different charge distribution patterns (Figure 2.4b, red points).  These 
results confirm that the distribution of cationic groups on the surface of a supercharged protein, 30 
 
and not simply the theoretical net charge of the protein, contributes to its cellular uptake 
properties.   
To account for the possibility that interaction between densely substituted cationic 
residues influences their protonation state and the net charge of scGFPs, we performed cation 
exchange and found that all proteins eluted in a manner consistent with their relative theoretical 
net charge rather than with their observed level of cellular uptake (Figure 2.5a).  Additionally, 
we tested whether the voltage of the scGFPs was affected by the distribution of charged residues, 
and found that some of the uptake deficiencies of weakly performing scGFPs can be accounted 
for using a model that describes the electric field of a protein in solution (Figure 2.5b, see 
Methods for details of model)   
Taken together, these findings are consistent with a model in which at least one cellular 
uptake potency-determining event, such as proteoglycan binding or receptor crosslinking21, is 
dependent on the arrangement of cationic groups on the surface of a supercharged protein, and 
not simply on its net charge.   31 
 
 
Figure 2.5 The effect of surface charge distribution on actual protein charge and protein voltage. 
(a) Charge-dependent elution of scGFPs and poly-Lys/Arg peptides from cation exchange resin. Each 
protein was loaded onto a HiTrap SP XL cation exchange column (GE Healthcare) in a 100 L volume at 
50 M protein concentration.  Proteins were eluted over a gradient from 1x PBS to 1x PBS with 1 M 
NaCl.  Protein elution was monitored by absorbance at 280 nm. Green points represent scGFPs.  Red 
points represent poly-Lys/Arg peptides.  (b) The effect of surface charge distribution on protein voltage 
and cellular uptake.  HeLa cells were treated with 200 nM of one of three +25 GFP variants (+25, +25a, 
or +25b GFP) or one of three +36 GFP variants (+35, +36, or +37 GFP). A positive relationship between 
protein voltage and cellular uptake is evident that is not apparent when considering only the theoretical 
net charge (open data points, top axis). 
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The cell-penetration properties of macromolecule delivery agents can depend strongly on 
the associated cargo12.  To determine whether the observed charge-uptake relationship for 
scGFPs is sustained for scGFP-mediated delivery of fused proteins, a subset of scGFPs were 
fused to either mCherry or to Cre recombinase22,23.  GFPs with theoretical net charges of +9, 
+15, +24, +25 (three variants designated +25, +25A, and +25B), +35, +36, +37, and +48 were 
chosen as fusion partners to cover a range of theoretical net charges, and to include some 
variants with altered charge distributions that performed below the level predicted by their 
theoretical net charge alone.  For comparison, the CPPs Tat, Arg10, and penetratin were also 
prepared as fusions with mCherry and Cre recombinase.   
HeLa cells were incubated with mCherry fusions for 4 hours at 50 nM to 2 µM, washed, 
and analyzed by flow cytometry using mCherry fluorescence as a measure of protein delivery.  
The mCherry fusions retained the same general trend of charge-dependent cellular uptake 
observed for scGFPs alone, with low-potency delivery transitioning to high-potency delivery (up 
to 50-fold more potent) for variants with > +15 theoretical net charge (Figure 2.6a).  We also 
observed lower cell penetration potency of the same high-charge variants that underperformed in 
the cellular uptake study described above (+25A, +25B, +35, +37, and +48 GFPs).  Fusions with 
CPPs performed as previously observed, with low overall mCherry delivery potency comparable 
to that of the +9 GFP-mCherry fusion, except for penetratin-mCherry, which resulted in 
moderate levels of delivery at the highest concentrations tested (1 to 2 µM).   
Next we used scGFP-Cre recombinase fusions to assay the functional delivery of protein 
enzymes to the cytosol.  BSR.LNL.tdTomato cells12 were used to report Cre-dependent 
recombination.  Since scGFP-Cre fusions have little or no recombinase activity until the scGFP 
moiety is cleaved from the recombinase moiety12, we first digested the purified proteins with 33 
 
 
 
Figure 2.6 Charge-dependence of fused protein uptake and functional delivery. (a) HeLa cells were 
treated with the indicated scGFP-mCherry for 4 hours, washed, and analyzed by flow cytometry. The plot 
shows median mCherry fluorescence of cells relative to untreated cells.  (b) BSR.LNL.tdTomato Cre 
reporter cells were treated with scGFP-Cre fusions for 4 hours incubated an additional 48 hours, and 
assayed by flow cytometry.  (c) BSR.LNL.tdTomato reporter cells were treated and analyzed exactly as in 
(b) except 100 M chloroquine was added during the 4-hour protein incubation and for an additional 12 
hours post-treatment. 
 
Figure 2.7 In vitro activity of Cre protein fusions and peptide conjugates.  The activity of purified Cre 
recombinase fusions and Cre conjugates to poly-Lys/Arg peptides was analyzed using an in vitro plasmid 
recombination assay.  Following 1 hour incubation at 37 °C, the reaction was analyzed by gel 
electrophoresis and the amount of recombined plasmid was determined by densitometry.  The data is 
normalized relative to the activity of wild-type Cre.  All proteins were pre-treated with cathepsin B to 
cleave the fused scGFP domain,  
 34 
 
 
cathepsin B to cleave the linker between scGFP and Cre and assayed the resulting proteins in 
vitro as previously described12.  All cathepsin B-digested scGFP-Cre fusions exhibited 
recombinase activities comparable to that of wild-type Cre (Figure 2.7).  In addition to being 
cleaved from scGFP, delivered Cre recombinase must also tetramerize, escape endosomes, 
translocate to the nucleus, and recombine the reporter gene cassette to trigger tdTomato reporter 
gene expression.  Cells were incubated with each of the scGFP-Cre fusions across a range of 
concentrations for 4 hours, washed to remove non-internalized proteins as before, then incubated 
further in protein-free media for 48 hours.   
The percent of recombinant cells resulting from each treatment was revealed by flow 
cytometry.  The Tat, Arg10, and penetratin Cre fusions exhibited functional recombinase delivery 
efficiencies in the low-potency regime, consistent with previously reported results11,12).  
Functional Cre delivery by scGFPs, in contrast to mCherry delivery, was strictly charge-
dependent, with higher charged scGFPs producing more recombinant cells, and like-charged 
variants clustering together (Figure 2.6b).  Interestingly, variants that were observed to be 
internalized with significantly lower efficiency than +36 GFP, such as +37 GFP and +48 GFP, 
when fused to Cre resulted in comparable or even greater recombinant cells than +36 GFP, 
respectively.  The differences between the cellular uptake potencies of these scGFPs (Figure 
2.6a) and their strictly charge-dependent ability to deliver functional Cre (Figure 2.6b) suggests 
that protein-intrinsic factors downstream of internalization, such as cleavage of the fusion or 
endosomal escape efficiency, are potency-limiting in the latter case.   
To test these possibilities, Cre delivery was repeated in the presence of chloroquine, a 
small molecule that enhances endosomal escape and increases functional delivery potency of 35 
 
supercharged proteins12.  Importantly, the profile of charge- and dose-dependent Cre 
recombination (Figure 2.6b) is significantly shifted towards greater functional delivery in the 
presence of 100 µM chloroquine (Figure 2.6c), and closely reflects the pattern of total fusion 
protein uptake (Figure 2.6a).   
To probe potential differences in cleavage efficiency of Cre fused to different 
supercharged proteins, we subjected +15 GFP-Cre and +36 GFP-Cre to in vitro and cell-based 
cleavage assays.  Both proteins were found to be equally cleavable (Figure 2.8a, b), suggesting 
that proteolytic cleavage efficiency is not a determinant of the different observed functional 
delivery abilities.  We also assayed the effect of blocking cleavage by co-incubation of BSR 
reporter cells with +36 GFP-Cre and a broad cathepsin inhibitor, Z-Phe-Gly-NHO-Bz24.  At low 
doses (0.1-0.5 µM) there is a clear depression of delivery (Figure 2.9), presumably due to a 
failure to liberate Cre from +36 GFP.  At high doses (2-100 µM), the efficiency of Cre delivery 
is dramatically improved, possibly due to continued inhibition of endosomal proteases that 
would otherwise degrade Cre.   
 
Figure 2.8 Protease susceptibility  of scGFP-Cre fusions.   (a) In vitro  cathepsin B cleavage assay 
showing the pH dependence of scGFP-Cre cleavage.  Cleavage reactions analyzed by PAGE and stained 
by Coomassie blue.  Pure preparations of scGFP-Cre, Cre, and scGFP proteins are included as references 
for cleavage products (b) Immunoblot of HeLa cell lysates treated for 1 hour with 0.5 µM scGFP-Cre, 
washed, and then incubated for the indicated period of time prior to harvesting of lysate. 36 
 
 
Figure 2.9 The effect of protease inhibition on +36 GFP-Cre delivery.  BSR reporter cells were 
incubated with the indicated dose of  +36 GFP-Cre protein and Z-Phe-Gly-NHO-Bz cathepsin inhibitor 
for 4 hours in serum-free media, and then incubated a further 48 hours prior to analysis of recombinant 
cells by flow cytometry.  Plots show % recombination as a function of inhibitor dose for three +36 GFP-
Cre treatments (250 nM, 500 nM, and 1000 nM protein). 
 
Taken together, these results suggest that functional protein delivery by scGFPs is 
charge-dependent and protease-dependent, and that this dependence is at least partially the result 
of post-internalization processes.  Processes that are likely to influence the intracellular survival 
and functional delivery of a protein, such as endosomal trafficking, maturation, or escape, may 
therefore be affected by the presence of highly cationic molecules within endosomes, a 
hypothesis explored in the experiments below. 
The above studies implicate theoretical net charge as a strong determinant of cell 
penetration and protein delivery potency.  Next we sought to determine the effect of protein 
structure on cell ular uptake and and protein delivery potency by measuring the delivery 
efficiency of proteins fused to Arg- and Lys-rich peptides with Lys/Arg content comparable to 
that of scGFPs.  Because genes encoding simple fusions of mCherry or Cre to polycationic Arg 
or Lys peptides longer than 10 amino acids did not express efficiently in E. coli, we used an 
enzyme-mediated protein ligation strategy to generate these proteins.  The synthetic peptides 37 
 
(KKR)3R, (KKR)6KR, and (KKR)9KRR were efficiently conjugated to mCherry and Cre using a 
highly active mutant sortase enzyme recently evolved in our laboratory (Supplemental 
Information Experimental Procedures)25.  The resulting poly-Lys/Arg-fused mCherry and Cre 
proteins were incubated with reporter cell lines as described above.  For comparison, cells were 
also treated with mCherry and Cre fused to +9, +15, +25, or +36 GFP, which collectively span 
the range of theoretical net charges covered by the poly-Lys/Arg-fused proteins.  Cellular uptake 
and protein delivery potencies were quantitated by flow cytometry as before.   
For mCherry delivery, scGFP fusions consistently outperformed fusions with similarly 
charged poly-Lys/Arg-conjugated mCherry (Figure 2.10a).  This difference was especially 
pronounced at lower concentrations.  While at higher concentrations fusions with +20 and +30 
peptides approached the performance levels of fusions with +25 GFP, in most cases and at most 
concentrations scGFPs resulted in more mCherry delivery than both similarly charged and more 
highly charged cationic peptides (Figure 2.10b).  These results indicate that scGFP proteins 
result in distinctly more potent cellular uptake and mCherry delivery than unstructured cationic 
peptides, even when the scGFP and the cationic peptides possess a similar theoretical net charge. 
The results for Cre recombinase delivery were generally consistent with the mCherry 
delivery results; scGFP-Cre fusions typically outperformed cationic peptide-Cre fusions, 
especially at lower doses, with the exception of the lower potency +9 and +15 GFPs (Figure 
2.10c).  Interestingly, the +20 and +30 poly-Lys/Arg peptides exhibited decreased Cre delivery 
potency compared with +10 poly-Lys/Arg, which is approximately as effective as Arg10-Cre 
(Figure 2.6b), despite the fact that all Cre conjugates and fusions were comparably active in 
vitro following cathepsin B treatment (Figure 2.7)12.  A possible explanation for the lower 
potency of the +20 and +30 poly-Lys/Arg peptides is their potential cytotoxicity, as has been 38 
 
previously reported for certain cationic peptides and other synthetic cationic polymers15,26.  This 
toxicity may not have manifested on the shorter timescale of the mCherry internalization assays, 
while the Cre assay is necessarily a multi-day experiment.   
 
Figure 2.10 scGFPs deliver mCherry and Cre recombinase more effectively than similarly charged 
cationic peptides.  Cells were treated and analyzed as described in Figure2.6a and b.  (a) Median 
mCherry fluorescence of cells treated with scGFP-mCherry fusions or cationic peptide-mCherry 
conjugates at the indicated doses for 4 hours.  (b) mCherry delivery efficiency as a function of protein net 
charge. (c) Percent recombinant BSR.LNL.tdTomato reporter cells expressing tdTomato following 
treatment with scGFP-Cre fusions or cationic peptide-Cre conjugates.  Error bars represent the standard 
deviation of three experiments. 
 
Collectively, these results reveal a cellular uptake and protein-delivery potency advantage 
from displaying positive charge on a structured protein surface, as is this case with scGFPs, over 39 
 
simply appending the same number of cationic residues in a simple, presumably unstructured 
peptide tag.  This difference may be explained if the higher density of Arg and Lys side chains in 
a short peptide prevents the complete protonation of every residue by decreasing their pKa values 
to reduce unfavorable charge-charge repulsion, decreasing the actual cationic net charges 
attainable by synthetic peptides compared with supercharged proteins.  Alternatively, spreading 
cationic residues over a much larger surface area may engage cell-surface receptors or other 
proteins involved in endocytosis and/or escape from endosomes more effectively than 
concentrating cationic charge in a small peptide tail.  We tested the former possibility using the 
same cation-exchange-based approach that we used to assess the actual charge magnitudes of 
scGFPs.  Poly-Lys/Arg peptides eluted from the cation exchange resin in a manner consistent 
with their theoretical net charge (Figure 2.5a).   These results support a model in which the 
potency differences between cationic peptides and supercharged proteins arise from differences 
in their ability to interact with cellular components rather than from differences in their actual 
versus theoretical net charge. 
We previously reported that scGFP uptake is an energy-dependent process that requires 
actin polymerization and the presence of cell-surface sulfated proteoglycans13.  Given these 
findings, one possibility is that scGFP may be taken up via macropinocytosis, similar to some 
CPPs27,21.  In light of the observed cellular uptake and macromolecule delivery differences 
between scGFPs and cationic CPPs, however, we hypothesized that significant mechanistic 
differences in their cellular internalization may also exist.  We therefore probed the uptake of 
scGFP in greater detail.   
We used a collection of known endocytic inhibitors to probe the role of different 
endocytic pathways in the uptake of scGFP.  HeLa cells were pre-treated with each inhibitor for 40 
 
1 hour prior to incubation with 500 nM +36 GFP and inhibitor for an additional hour (Figure 
2.11a).  Cells were washed as described above and scGFP uptake was measured by flow 
cytometry.   
 
Figure 2.11 Effects of endocytic pathway probes on mCherry delivery by +36 GFP.  (a) Cells were 
pre-treated for 1 hour with the indicated inhibitor prior to 1-hour treatment with 500 nM +36 GFP in the 
continued presence of inhibitor, washed, and analyzed by flow cytometry.  A mutant cell line, CHO 
pgsA–, which lacks heparin sulfate proteoglycans, and treatment at 4 °C instead of 37 °C, were included 
as controls (grey bars). (b) HeLa cells co-treated with Texas Red-labeled transferrin and the indicated 
cationic protein or peptide for 4 hours were washed and analyzed by flow cytometry. 
 
Amiloride prevents the activation of macropinocytosis28 that are implicated in the uptake 
of cationic CPPs, and inhibits Tat peptide delivery nearly completely at 5 mM27.  In contrast, 5 
mM amiloride reduced uptake of scGFP by only 48%.  Likewise, cytochalasin D, an inhibitor of 
actin polymerization, blocked uptake of scGFP by 45% at 10 µM,, but has been reported to block 
Tat peptide uptake by >90%27.  These findings suggest that, in contrast to most cationic CPPs, 
scGFP uptake is not entirely dependent on macropinocytosis and actin-dependent processes.  
Interestingly, 5 µg/mL chlorpromazine, which prevents the formation of clathrin-coated pits, and 
50 µM dynasore, which prevents the scission of clathrin-coated vesicles29,30, inhibited uptake of 41 
 
+36 GFP by 78% and 62%, respectively. Finally, nystatin and filipin, two inhibitors of caveolin-
dependent uptake which is involved in the internalization of some viral delivery agents and non-
viral protein-based agents31,32, resulted in no observable impact on scGFP uptake at 50 nM of 
either inhibitor.  These inhibitor studies collectively implicate a clathrin-dependent endocytosis 
as a major mechanism for the uptake of scGFP, and suggest that macropinocytosis plays a lesser 
role.  
To test whether scGFPs modulate clathrin-dependent uptake, we incubated HeLa cells 
with fluorophore-labeled transferrin, a known clathrin-dependent cargo, and Tat-mCherry, 
penetratin-mCherry, (KKR)9KRR-mCherry, +15 GFP, or +36 GFP at concentrations from 0.1 to 
2 µM (Figure 2.11b).  Co-incubation with +36 GFP resulted in a marked dose-dependent 
increase in intracellular transferrin.  None of the other proteins tested had an appreciable effect 
on transferrin uptake.  Titration of transferrin (20 to 200 µg/mL) in the presence of 200 nM +36 
GFP had little effect on +36 GFP uptake, indicating that +36 GFP does not use the same receptor 
as transferrin but instead stimulates transferrin accumulation independently.  The stimulation of 
transferrin accumulation by +36 GFP may implicate clathrin in the uptake of scGFP and suggests 
that high-potency scGFPs potently alter endocytic processes that rely on this pathway.  These 
results also represent a distinction between high-potency scGFPs and other proteins and peptides 
tested.   
Given the partial inhibition of +36 GFP uptake by the macropinocytosis inhibitor 
amiloride (Figure 2.11a), we tested the effect of epidermal growth factor (EGF), a known 
inducer of macropinocytosis, on +36 GFP uptake.  Across a range of concentrations (0.1 to 1 
µg/mL), EGF had no significant impact on +36 GFP uptake (Figure 2.12a).  However, when the 
internalization of labeled EGF was studied as function of the concentration of +36 GFP, +15 42 
 
GFP, Tat-mCherry, penetratin-mCherry, and (KKR)9KRR-mCherry (0.1 to 2 µM each), EGF 
uptake was inhibited by +15 GFP , +36 GFP, and (KKR)9KRR-mCherry by up to 40% (Figure 
2.12b).  This observation indicates that high-potency cell-penetrant proteins such as +36 GFP 
may either compete with EGF for receptors, strongly induce ligand-independent internalization 
of EGF receptors through (a known mechanism of EGFR regulation)33,34, or alter EGFR 
activation, internalization, or degradation through another mechanism.   
 
Figure 2.12 Interaction between scGFP and EGF uptake. (a) HeLa cells in serum-free DMEM were 
treated with 200 nM +36 GFP in the presence of EGF ranging from 100 ng to 1 mg/mL, then washed and 
assayed by flow cytometry to determine GFP uptake.  + 36 GFP uptake is normalized to 200 nM +36 
GFP uptake in the absence of EGF treatment. (b)  HeLa cells co-treated with Alexa 594-labeled EGF and 
the indicated cationic protein or peptide for 4 hours were washed and analyzed by flow cytometry.  EGF 
uptake  was  normalized  to  cells  treated  with  Alexa  594-labeled  EGF  alone.  Error  bars  represent  the 
standard deviation of three experiments. 
 
Collectively, these mechanistic studies indicate that high-potency scGFPs enter cells 
through uptake pathways that include clathrin-dependent endocytosis, which may be altered by 
scGFPs, and macropinocytosis.  Furthermore, scGFPs cause significant changes to the transport 43 
 
of both recycling and degradative endocytic cargoes.  Such changes correlate with the potency of 
protein delivery. 
The above observations suggest that scGFPs enter cells through specific endocytic routes.  
Next we characterized the effects of scGFPs on key protein components in endocytosis 
pathways.  Charged peptides including Tat and Arg10 have been shown to induce the activation 
of Rac GTPase21, an early step required for the induction of macropinocytosis.  Rho and Rac are 
GTPases involved in cytoskeletal reorganization and endosomal trafficking36,37.  Rac is located 
near the plasma membrane and initiates actin polymerization at the start of macropinosome 
formation38.  Rho is downstream of multiple endocytic pathways, including caveolin-dependent 
uptake, and clathrin-independent phagocytosis of particulate matter39.  Rac, on the other hand, is 
associated with fluid-phase endocytosis38.  
We assayed the activation of the GTP-bound form of Rho and Rac GTPases by scGFPs 
and poly-Lys/Arg peptides using a colorimetric plate-based “GLISA” (Cytoskeleton, Inc.).  The 
initial binding events of scGFP and cationic peptides depend on association with sulfated 
proteoglycans13, and the binding and crosslinking of proteoglycans is known to activate 
endocytosis40,41.  We therefore used CHO cells as well as mutant CHO pgsA- cells defective for 
xylosyltransferase42, which is responsible for sulfation of proteoglycans, as a control.  Cells were 
incubated for 5 minutes with proteins, harvested, and lysed.  The resulting cell lysates were 
applied to GLISA plates.  Upon treatment with high-potency scGFPs and poly-Lys/Arg peptides, 
Rho was activated roughly 2-fold compared with untreated controls (Figure 2.13a).  Low-charge 
variants resulted in significantly lower activation levels, consistent with the observed sigmoidal 
charge-uptake relationship for scGFP (Figure 2.3 and 2.4a).  Treatment of the CHO pgsA- cells 
resulted in low Rho activation across all treatments, indicating that Rho activation is dependent 44 
 
on sulfated proteoglycans (Figure 2.13a, dark bars).  Importantly, the activation of Rho by 
scGFPs is consistent with our observation of a +36GFP-dependent intracellular transferrin 
accumulation (Figure 2.11b), as Rho plays an important role in clathrin organization, cargo 
sorting, and endosome motility39. 
 
Figure 2.13 activation of Rho-GTP and ERK1/2 phosphorylation by scGFPs and cationic peptides. 
CHO cells (light bars) or CHO pgsA– cells (dark bars) were treated with 1 M of the indicated scGFP or 
cationic peptide.  EGF treatment at 50 ng/mL was included as a control for endocytosis activation 
(“EGF”).  (a) Rho-GTP quantitation by GLISA.  (b) Rac-GTP quantitation by GLISA. (c) The extent of 
ERK1/2 phosphorylation determined by immunoblot with anti-phospho ERK1/2 antibody and quantitated 
by densitometry.  Error bars represent the standard deviation of three experiments. 
 
We also assayed the activation of GTP-bound Rac by GLISA following treatment with 
scGFPs or poly-Lys/Arg peptides, and observed no activation by scGFPs and weak activation by 45 
 
poly-Lys/Arg peptides (Figure 2.13b), consistent with observations by others that Rac activation 
increases following treatment with either Arg8 or Tat peptides21.  Rho and Rac are known to 
negatively regulate one another43, and significant Rho activation may depress Rac levels.  Given 
the role of Rho in the activation and maturation of different endocytic pathways39,38, the above 
results could provide a molecular explanation for the scGFP-mediated alteration of transferrin 
and EGF endocytosis (Figure 2.11b and 2.12b).   
In many cell lines, endocytosis is required for full activation of ERK1/2 following 
receptor ligation44,45,46.  Therefore, changes in ERK1/2 phosphorylation can reflect activation of 
plasma membrane signaling receptors by scGFPs or changes in the endocytic transport of these 
receptors47. 
We measured ERK1/2 phosphorylation by immunoblot analysis of cell lysates treated for 
5 minutes with scGFP or poly-Lys/Arg variants to quantitate phospho-ERK1/2 levels.  Upon 
treatment with highly charged scGFPs, but not similarly charged poly-Lys/Arg peptides, cellular 
ERK1/2 was phosphorylated by up to 8.4-fold over controls lacking treatment (Figure 2.13c).  
More modestly charged (+9 or +15) scGFPs also induced ERK1/2 phosphorylation, although to a 
lower extent (Figure 2.13c).  In all cases tested, ERK 1/2 phosporylation was also dependent on 
the presence of sulfated proteoglycans, as evidenced by the lack of ERK1/2 phosphorylation in 
the CHO pgsA- cells (Figure 2.13c, dark bars).  This finding suggests that the activation of 
receptor signaling, and possibly receptor internalization, is an important factor in scGFP uptake.  
These results also provide additional mechanistic distinctions of scGFP uptake compared with 
the uptake of unstructured cationic peptides, which have no significant effect on ERK1/2 
phosphorylation.   46 
 
The amount of material per endosome, the rate of intracellular transport and maturation, 
and the ultimate destination of endocytosed material are all parameters known to vary among 
endocytic routes48.  These distinctions can impact the characteristics and effectiveness of protein 
delivery.  A comparison of scGFP uptake, scGFP-mCherry uptake, and functional Cre delivery 
(Figures 2.3, 2.4a, and 2.6a-c) suggests charge-dependent differences following internalization 
that contribute to the effectiveness of extraendosomal functional delivery of protein cargoes.  
The high charge of cationic delivery reagents could alter the ionic composition of the endosomal 
lumen.  As the trafficking of endosomes is closely tied to the function of endosomal membrane 
ion channels and pumps49, significant alteration through such a mechanism could disrupt 
endosome transport and maturation.    Endocytosed cargoes targeted for degradation are 
transported to perinuclear lysosomal compartments within approximately 2 hours50.  The 
effective cytosolic delivery of endocytosed material requires that it avoids degradation in the 
endocytic pathway.   A difference in the transport to lysosomes between scGFPs and cationic 
peptides may explain the observed variations in protein delivery data described above. 
We monitored the transport of proteins to lysosomes following internalization by 
incubation of HeLa cells with 500 nM of a protein of interest for 1 hour.  Following this 
incubation, cells were washed extensively with PBS containing heparin, and incubated a further 
4 hours in protein-free media containing heparin to prevent the uptake of any remaining 
extracellular protein and inhibit the reinternalization of material from recycling endosomes.  
Dextran, a marker of fluid-phase endocytosis51, was included as a control.  Lysosomes were 
labeled with the LysoTracker reagent (Life Technologies), which effectively labels acidified 
lysosomes.   47 
 
 
Figure 2.14 Lysosomal localization of scGFPs and cationic peptides.  (a) HeLa cells were treated with 
scGFP proteins or peptide-mCherry fusions for 1 hour, washed, incubated an additional 4 hours and 
imaged by confocal microscopy.  Lysosomes were labeled with LysoTracker Red or Green as appropriate 
(Life Technologies).  The colocalization of proteins with lysosomes was determined by calculation of the 
Pearson’s correlation coefficient of the red and green channels using ImageJ (left).  A representative 
image of cells treated with either FITC-dextran (top right) or +36 GFP (bottom right) is shown. (b) Long 
term survival of scGFP within endosomes. HeLa cells treated with +36 GFP for 1 hour were washed and 
incubated for up to 16 additional hours in DMEM with 1% FBS to prevent dilution through cell division 
and 20 U/mL heparin to prevent continued endocytosis of residual extracellular +36 GFP protein.  Cells 
were analyzed by flow cytometry, and normalized by the median fluorescence of cells immediately 
following the 1-hour incubation (time = 0). Error bars represent the standard deviation of three 
experiments. 
We performed co-localization analysis of Lysotracker dye with the scGFPs and cationic 
peptide-tagged mCherry proteins to determine the extent of endosomal trafficking or maturation 
disruption (Figure 2.14a).  Dextran efficiently co-localized with lysosomes, resulting in a 
Pearson's correlation coefficient (ρ) of 0.8.  In contrast, all delivered proteins displayed some 
level of significantly slower transport, with none exhibiting ρ > 0.6.  In all cases, large numbers 
of protein-containing peripheral endosomes were observed, even 4 hours after removal of the 
protein reagent from the media.  Such a failure to localize to perinuclear acidic vesicles suggests 
either a slowing of the maturation of protein-containing endosomes or the sorting of scGFPs 
away from the degradative pathway.  The observation of a peripheral vesicles was not due to 
continued or recent internalization of proteins since the cells were incubated in protein-free 
media following washing and prior to imaging.  Likewise, the apparent peripheral distribution 48 
 
was not due to the degradation and disappearance of otherwise perinuclear lysosomal material 
over time, as the total cellular fluorescence did not significantly decrease over the course of the 
4-hour incubation following treatment (Figure 2.14b).   
The extent of lysosomal colocalization was significantly lower for all scGFPs compared 
with any cationic peptide tested (Figure 2.14a).  The scGFPs exhibited the least lysosomal co-
localization with a trend of decreased lyosomal localization with increased charge.  Within the 
CPP set of Tat, Arg10, and penetratin, the trend of colocalization strongly reflected functional 
delivery properties, with Tat (the most potent delivery agent of the cationic peptides in this 
study) exhibiting the lowest lysosomal colocalization.  The colocalization data for the poly-
Lys/Arg peptides, in contrast, did not follow this trend.  While all poly-Lys/Arg peptides showed 
significantly reduced lysosomal co-localization compared to dextran, they were among the 
poorest performing domains in the Cre recombinase delivery assays (Figure 2.10). 
Collectively, these lysosomal localization results reveal that the relative delivery abilities 
of scGFPs and CPPs correlate with the extent of slowed endosomal maturation, and that scGFP 
exhibits a stronger effect on these processes than CPPs.  That such an effect correlates with the 
potency of functional delivery suggests that the ultimate non-endosomal fate of delivered 
proteins relies at least in part on how they are trafficked after internalization. 
After observing the strong effect on endosome transport to lysosomes among the cationic 
delivery reagents tested, we characterized the events of early endocytosis and tracked differences 
between scGFPs and CPPs leading up to the observed late-stage endosomal distribution using a 
recently reported high-throughput confocal microscopy image analysis pipeline(Figure 2.15, see 
Methods for detailed description of analysis pipeline)48.  This platform enables the measurement 
of a wide range of endosomal parameters, including trafficking kinetics, endosome number, size 49 
 
distribution, and content.  As representative proteins, we applied this strategy to the study of +36 
GFP (a high-potency supercharged protein), +15 GFP (a modestly potent supercharged protein), 
Tat-mCherry, penetratin-mCherry, and +30 (KKR)9KRR-mCherry (three cationic peptides of 
varying charge and size)  
 
 
Figure 2.15 High throughput confocal microscopy images subjected to trafficking analysis.  Sample 
of representative images assayed for localization of scGFPs with early or late endosomal markers. HeLa 
cells treated with 500 nM of the indicated protein and subjected to high throughput confocal microscopy 
as  EEA1 is pseudo-colored red, LAMP1 is pseudo-colored blue, and +36 GFP signals are pseudo-colored 
green.  Scale bars represent 10 micrometers. 
  HeLa cells were incubated with 0.1 to 2 µM of each protein for 30 minutes, washed, and 
fixed.  Over a range of concentrations, the number of scGFP or CPP-containing vesicles 
increased steadily (Figure 2.16a).  Among the proteins tested, +36 GFP occupied the highest 
number of endosomes, even at low concentration (0.1 µM), while other proteins did not occupy 
such a high number of endosomes even at the highest dose (2 µM).  The +30 poly-Lys/Arg 
peptide exhibited a decrease in the number of endosomes formed at high doses.  Tat was only 
detected in a small number of endosomes, consistent with its modest cell-uptake potency.   
Importantly, over a range of protein concentrations, the amount of protein per endosome 
did not exhibit a significant dose-dependent increase (Figure 2.16b).  Endosomes with +36 GFP 50 
 
contained roughly 4- to 10-fold more protein per endosome than endosomes with CPPs, while 
+15 GFP-containing endosomes had roughly 2-fold more protein than CPPs.  These findings 
have important implications for interpreting the concentration dependence of functional protein 
delivery.  While the amount of protein per endosome is likely a factor contributing to the overall 
effectiveness of protein functional delivery, as evidenced by the relative amounts of protein per 
endosome for +36 GFP and +15 GFP versus CPPs (Figure 2.16b), the number of endosomes 
containing endocytosed protein, rather than the amount of protein per endosome, more closely 
correlates with dose-dependent changes in functional delivery potency.  Increasing the dose of 
protein during treatments resulted in both more protein-containing endosomes and more potent 
functional delivery (Figure 2.16a and 2.6b, respectively). 
 
Figure 2.16 Effect of scGFPs and cationic peptide concentration on endosome formation and 
endosomal protein content. HeLa cells were incubated with the indicated concentrations of scGFP or 
peptide-mCherry fusion for 1 hour, washed, and the number of GFP or mCherry-containing endosomes 
was analyzed by high throughput microscopy (a) Supercharged proteins and cationic peptides are 
endocytosed with greatly different potencies.  (b) High-potency scGFPs fill individual endosomes with 
more protein than less potent scGFPs and cationic peptides.   
We next measured the uptake and trafficking of proteins over time.  Cells were incubated 
with 500 nM proteins for up to 2 hours.  +36 GFP rapidly entered cells, filling a maximal 
number of early endosomes (identified by the presence of EEA152) within 10 minutes of 
treatment (Figure 2.17).  The other proteins were much slower in their uptake, requiring as much 51 
 
as 2 hours before reaching maximal early endosome occupancy.  Thereafter, +36 GFP quickly 
exited early endosomal compartments.  The rapid uptake and transport to early endosomes of 
+36 GFP in comparison with the other proteins may reflect the ability of this protein to be 
mainly internalized by clathrin-mediated endocytosis, as described above (Figure 2.14a). 
 
Figure 2.17 Uptake and kinetics scGFPs and cationic peptides. HeLa cells were incubated with the 
indicated scGFP or peptide-mCherry fusion at 500 nM for up to 2 hours and analyzed by confocal 
microscopy.  
 
Over the course of two hours, a small fraction (< 20%) of +36 GFP eventually localized 
to late endosomes compartments (identified by the presence of LAMP1) (Figure 2.18).  
Interestingly, the vast majority of +36 GFP protein is unaccounted for in either of these major 
endosomal populations.  The other proteins tested were slow to enter both early endosomal 
compartments and late endosomal compartments, while a major portion of the protein was  52 
 
 
Figure 2.18 Trafficking kinetics of scGFPs and cationic peptides.  Trafficking of protein through early 
endosomes (labeled with anti-EEA1 antibody) and lysosomes (labeled with anti-LAMP1 antibody).  The 
number of GFP- or mCherry-containing vesicles showing EEA1 or LAMP1 colocalization was an 
analyzed by high-throughput automated confocal microscopy.  In all plots, green points represent the total 
number of vesicles containing scGFP or peptide-mCherry fusions; blue points are vesicles showing EEA1 
colocalization; and red points are vesicles showing LAMP1 colocalization.  All error bars represent the 
standard deviation of three experiments. 
 
retained outside of either of these endosomal populations, as with +36 GFP.  The amount of 
protein degradation post-endocytosis, as measured by loss of fluorescence, was not appreciable 
for any of the proteins within the 2 hours tested.  The lack of degradation over this period, and 53 
 
even over a longer 16-hour incubation (Figure 2.14b), suggests a role for dramatically slower 
lysosomal degradation in functional protein delivery.  Indeed, 80% of the original +36 GFP 
signal remained within cells after 16 hours, indicating very little proteolysis of the endocytosed 
cargo.  In contrast, the intracellular lifetime of other endosomal cargo is comparatively short.  
For example, transferrin can be recycled out of the cell rapidly, with an intracellular half-life of 7 
minutes53; EGF is almost completely degraded within 2 hours54; and polystyrene beads are 
transported to lysosomes within 2 hours50.  The presence of intact protein within an endosomal 
reservoir for several hours post-internalization may provide a much greater opportunity for these 
proteins to escape endosomes, even through a low-efficiency mechanism, than endosomal 
cargoes that are rapidly degraded through canonical pathways. 
Finally, we measured the amount of protein per endosome and the size of endosomes 
over time.  These two parameters are indicative of endosomal maturation and fusion, and may 
determine the long-term fate of endocytosed proteins.  Over 2 hours the average amount of 
protein in each cell did not decrease for any protein tested.  However, unique among all proteins 
tested, the number of +36 GFP-containing endosomes decreased sharply (Figure 2.18).  
Consequently, the amount of +36 GFP per endosome increased dramatically over time (Figure 
2.19a).  This protein concentration effect was much less pronounced for the other proteins tested, 
with +36 GFP reaching > 5-fold more protein per endosome than any other agent tested, and 
achieving a 5-fold increase in the amount of protein per endosome over 2 hours.  The other 
agents exhibited a much more modest increase in the amount of protein per endosome during this 
time (Figure 2.19a).  These measurements suggest that +36 GFP is not significantly inhibiting 
homotypic fusion and cargo accumulation in endosomes.  The size of protein-containing 54 
 
endosomes did not change over time appreciably for any protein tested (Figure 2.19b), and all 
endosomes were smaller compared to both early and late endosomes.   
 
Figure 2.19 Time-dependence of endosomal protein content and size following treatment with 
scGFPs and cationic peptides. (a) Amount of GFP or mCherry protein per endosome as a function of 
time.  (b) Size of endosomes as a function of time, with the average size of early endosomes and 
lysosomes indicated by the dotted and solid lines, respectively.  All error bars represent the standard 
deviation of three experiments. 
 
These observations suggest a role for the long-term intracellular survival of proteins 
within a unique peripheral endosomal population during the process of functional protein 
delivery by supercharged proteins and cationic peptides.  The endosomes occupied by +36 GFP 
are indeed acidified exit the early unacidified endosomal population, as marked by EEA1, yet 
they are not effectively transported to late endosomes (Figure 2.18) or lysosomes (Figure 
2.14a).  Our observations for +36 GFP may reflect a unique trafficking alteration that is shared at 
least in part by other polycationic delivery reagents.  The specific cause and consequence of 
these changes is not obvious, but it is possible that a high concentration of cationic moieties 
within an endosome disrupts lumenal ion composition, preventing the maturation of protein-
containing endosomes and their subsequent fusion with degradative compartments.  If the intra-55 
 
endosomal survival of proteins is extended as a result, then the delivery of functional extra-
endosomal proteins may strongly depend on such alterations to endosomal trafficking.  
Finally, we have developed a method to adapt existing liposomal nucleic acid delivery 
techniques to the delivery of proteins.    
The surface chemistry of proteins varies dramatically between distinct protein sequences, 
making general, one-size-fits-all delivery formulations difficult to achieve.  While 
superpositively charged proteins can drive efficient internalization due to their extreme charge, 
the nature of the fused cargo protein can sometimes dominate the chemical properties and 
performance of the fusion protein.  Issues with solubility in physiologic conditions, sensitivity to 
degradation, and the potential immunogenicity of naked recombinant proteins may limit their 
broad application.   
In contrast nucleic acids can be treated as comparatively identical in terms of their bulk 
chemical properties due to their more uniform polymeric structure that is held in common even 
between highly divergent sequences. Nucleic acid delivery, when compared to protein delivery 
technologies is a much more mature technology.  The widespread, routine use of commercial 
cationic polymers and lipids is a testament to this.  Liposomes in particular are an attractive 
delivery platform, as the nature of lipid bilayer structure makes membrane-membrane fusion 
within endocytic vessels a natural and efficient means of endosomal escape.  Liposomes further 
stabilize and protect their cargo until the point of delivery, potentially reducing immunogenicity, 
degradation, and the effective dose of cargo delivered. 
We hypothesized that the endosomal escape properties inherent to liposomal formulations 
could be brought to bear on protein delivery if a method to drive efficient encapsulation of 56 
 
proteins could be developed.  Cationic lipid reagents drive efficient encapsulation of nucleic 
acids due to electrostatic interactions with the anionic phosphate backbone.  To mimic this 
interaction, we tested whether -30 GFP, originally developed as a counterpart to +36 GFP in the 
study of protein folding, could drive encapsulation of a fused cargo protein and mediate 
functional delivery via liposomes. 
We constructed a translation fusion of -30 GFP to Cre recombinase and assayed delivery 
as above using the BSR.LNL.tdTomato reporter cell line.  As an initial trial, Lipofectamine 
RNAiMAX (Life Technologies), an siRNA delivery reagent, was used to attempt encapsulation 
of the purified recombinant protein.  This particular liposomal formulation was chosen due to the 
comparable charge and size of siRNAs to -30 GFP, rather than plasmid DNA delivery reagents 
which are optimized for larger cargoes and greater negative charge.  Encapsulation protocols 
were followed exactly as recommended for siRNA cargo, substituting the purified protein 
instead. 
In intial tests, -30 GFP-Cre was found to be efficiently delivered by the liposomal 
formulation across a wide range of doses (Figure 2.20).  Surprisingly, the optimal dose of -30 
GFP-Cre when used with liposomes was 50-fold lower than that of naked +36 GFP Cre protein. 
Indeed, optimal delivery of -30 GFP Cre induced recombination in 50% of cells, compared to 
only 15% from +36 GFP Cre at a 50-fold higher treatment.  Interestingly, liposomal 
encapsulation drove more effient delivery of both +36 GFP-Cre and nonfused Cre recombinase, 
consistent with the general ability of liposomes to enhance endosomal escape.  However, only -
30 GFP-Cre was delivered efficiently at low doses.  At doses as low as 5 nM, -30 GFP-Cre is 
able to induce recombination at a rate comparable to that of a 1 µM +36 GFP-Cre treatment, a 
200-fold improvement in delivery.   57 
 
These remarkable results have prompted us to explore the delivery of other protein 
cargoes, including potential therapeutics, and to further optimize both the encapsulation process 
and liposomal formulation for eventual application in vivo.  
 
Figure 2.20 -30 GFP fusion enables efficient liposomal delivery of proteins.  The indicated 
protein was incubated with 1.5 uL of LipoFectamine RNAiMAX across a range of 
concentrations and subsequently used as per the manufacturers protocol.  Cells were treated for 4 
hours, media was replaced, and cells were subsequently analyzed by flow cytometry to detect 
recombinants. 
 
Discussion 
In this study we found that the cellular uptake ability of supercharged GFPs exhibits a 
strong sigmoidal charge dependence.  Such a relationship suggests distinct interactions with 
cellular components or uptake through different endocytic routes by high-charge, high-potency 
scGFPs compared with CPPs or low-potency scGFPs.  Indeed, our subsequent mechanistic 58 
 
studies revealed that high-potency scGFPs alone require clathrin and dynamin for efficient 
uptake, and modify the transport of clathrin-dependent endocytic cargoes.  The potency of 
scGFPs correlates with the level of activation of Rho and ERK1/2.  Such activation may involve 
the crosslinking of sulfated proteoglycans or other receptors on the cell surface, a process known 
to induce macropinocytosis by CPPs55.  If receptor crosslinking is indeed the basis of endocytic 
activation by supercharged proteins, then perhaps the extended surface area provided by highly 
charged variants explains their greater observed potency compared with more modestly charged 
scGFPs or unstructured, short cationic CPPs.  
The endocytosis inhibitor and transferrin uptake studies described above suggest that 
scGFP cellular uptake relies significantly on the induction of clathrin-dependent uptake.  While 
internalization of scGFPs is still dependent on the presence of anionic sulfated proteoglycans, the 
studies above suggest that the major route of scGFP uptake is not macropinocytosis.  These 
results, combined with the mechanistic studies implicating Rho and ERK1/2 activation, suggest 
that scGFP uptake likely proceeds through multiple pathways and depends most heavily on a 
proteoglycan-requiring, clathrin-dependent process. 
We observed that both scGFPs and CPPs undergo an altered process of trafficking 
following endocytosis.  The delivery agents tested here are not effectively transported to 
degradative lysosomal compartments.  Moreover, the endocytosed proteins are localized within 
abnormally small peripheral endosomes that are negative for the early endosome marker EEA1.  
The magnitude of the changes to endosomal transport correlates with the ability of each reagent 
to deliver cytosolic proteins.  This novel finding has important implications for the survival of 
delivered proteins within cells, and for macromolecular delivery vehicles in general.  If protein-
containing endosomes fail to mature and efficiently fuse with lysosomal compartments, then 59 
 
delivered proteins may be provided with an extended temporal window during which they can 
escape into the cytoplasm. Such a phenomenon could contribute to the effectiveness of all 
cationic delivery vehicles, especially high-potency supercharged proteins, which altered 
endosome trafficking more than the other proteins and peptides studied here.  The exact 
mechanism by which scGFPs and CPPs disrupt endosomal transport is not yet understood and 
represents an attractive subject of future studies.  Supercharged GFPs also caused significant 
changes to the transport of the endocytic cargoes transferrin and EGF, raising the possibility that 
supercharged proteins have multiple effects on specific molecular components of the endocytic 
system that lead to changes in transferrin receptor and EGF receptor recycling and degradation. 
Together, our findings reveal new insights into the mechanism of cellular uptake and 
trafficking of supercharged proteins and CPPs, and more generally highlight the importance of 
studying at the subcellular level the interaction of delivery agents with their target cells.  Such 
studies improve our understanding of how macromolecule delivery agents work, and identify 
means by which to optimize their function.  These studies also suggest ways in which exposure 
to such delivery agents can alter cell physiology, an important consideration as macromolecular 
medicines become increasingly pervasive human therapeutics. 
 
Methods 
Construction of scGFPs 
We used a simple PCR and restriction enzyme-based approach to rapidly generate each scGFP 
variant with a common cloning strategy.  Plasmids encoding stGFP, +15 GFP, +25 GFP, and +36 GFP, 
and +48 GFP were used as templates for PCR to generate three fragments spanning the full-length GFP 
sequence coding sequence.  The three classes of PCR products were bounded by pairs of endogenous 
restriction enzyme cleavage sites (NheI/NdeI, NdeI/EagI, or EagI/XhoI).  The appropriate sets of PCR 60 
 
products were digested with the requisite enzyme pair and ligated into a pET vector backbone to generate 
pET-+N GFP, where N is the theoretical net charge of the resultant protein calculated by summing the 
charge of all acidic and basic residues. The choice of restriction sites did not alter the sequence of the 
resulting protein.  
Construction of scGFP-mCherry and scGFP-Cre fusions 
A pET expression vector was prepared containing a (GGS)9 linker flanked at the 5’ by NheI and 
AgeI sites, and KpnI and BamHI at the 3’.  The coding sequences for mCherry and Cre were PCR 
amplified and cloned into the KpnI and BamHI site, to place them C-terminal of the linker.  The 
appropriate scGFP sequence was then cloned N-terminal of the linker into NheI and AgeI sites to generate 
the sets of scGFP-mCherry and scGFP-Cre expression constructs. 
Generation of poly-Lys/Arg-linked mCherry and Cre using an evolved sortase enzyme 
For proteins with N-terminal peptides, pET expression plasmids were generated by PCR 
amplification of the coding sequence of either mCherry or Cre using primers that add a triglycine 
sequence to the N-terminus (MGGG-, where M should be efficiently removed by E. coli processing 
machinery), and a 6xHis tag sequence to the C-terminus.   
For proteins used with C-terminal peptide tags, pET expression plasmids were generated by PCR 
amplification of the coding sequence of either mCherry or Cre, with primers to add the sequence –
LPETGGSHHHHHH to the C-terminus.  Such a sequence is a substrate for sortase, which removes the 
6xHis tag, and appends GGG-poly-Lys/Arg peptide to generate –LPETGGG-poly-Lys/Arg. 
Poly-Lys/Arg peptides were synthesized by the Tufts University Proteomics Core.  For N-
terminal peptides, the poly-Lys/Arg sequence was immediately followed by the sequence LPETGG, for 
sortase recognition, cleavage and ligation to GGG-terminated proteins.  For C-terminal peptides, the poly-
Lys/Arg sequence was preceded by GGG to enable it to act as the nucleophile in the sortase tagging 
reaction, resulting in ligation to the C-terminus of the protein. 
All sortase tagging reactions took place using the following conditions: 100 μM of the appropriate 
N-terminal GGG- or C-terminal LPETG-bearing protein, 2 mM of the appropriate LPETG- or GGG-61 
 
bearing peptide, 5 mM CaCl2, 5 μM evolved sortase enzyme, 1xTBS, incubated at 25 °C for 1 hour.  
Following the incubation, EDTA was added to 1 mM and reactions were placed on ice for 5 minutes.  
Unconjugated peptide was depleted by concentrating and re-diluting the reactions three times in 30 kDa 
cutoff microcentrifuge concentrator tubes (Millipore), for a total of ~1,000-fold dilution of the excess 
peptide.  The reaction was then purified by cation exchange to remove the unreacted proteins or peptides 
and the sortase enzyme.     
Protein expression and purification 
Briefly, E. coli BL21(DE3) was transformed with the appropriate pET expression vector.  
Purification involved His-tag affinity chromatography using Ni-NTA agarose, followed by cation 
exchange to remove contaminating anionic E. coli components that may confound downstream 
mammalian cell-based assays.  Protein purity was monitored by SDS-PAGE and Coomassie Blue 
staining.    
Protein uptake and delivery assays 
Briefly, scGFP and scGFP-mCherry delivery assays were performed with HeLa cells.  Proteins 
were diluted in serum-free DMEM and incubated on the cells in 48-well plates for 4 hours at 37 °C. 
Following incubation, the cells were washed three times with PBS + 20 U/mL heparin and trypsinized for 
analysis of protein uptake by flow cytometry. 
Cre delivery assays used the BSR.LNL.tdTomato cell line.  Cre fusion proteins were diluted in 
serum-free media on the cells in 48-well plates for 4 hours at 37 °C.  Following treatment, the cells were 
incubated a further 48 hours in serum-containing media prior to trypsinization and analysis by flow 
cytometry. 
All flow cytometry were carried out on a BD Fortessa flow cytometer (Becton-Dickinson) using 
530/30 nm and 610/20 nm filter sets. 
Rho, Rac, and ERK1/2 activation 
Rho and Rac activation assays were performed using colorimetric Rho and Rac GLISA kits 
(Cytoskeleton).  CHO and CHO-pgsA– cells were plated in 60 mm plates at 4 x 104 cells per plate.  Cells 62 
 
were grown for 24 hours in DMEM-F12 with 1% FBS, and then 16 hours in serum-free DMEM-F12 to 
serum-starve prior to treatment.  Media was aspirated from cells, and the appropriate protein treatment 
diluted in pre-warmed serum-free DMEM-F12 was applied to the cells in plates.  Immediately following a 
5-minute incubation, cells were placed on ice, media was aspirated, and cells were washed three times in 
ice cold PBS + heparin to remove surface bound proteins.  Cells were lysed in 100 μL of the provided 
lysis buffer, scraped from the plate, transferred to chilled 1.5 mL tubes and immediate frozen in liquid 
nitrogen.  The assays were performed exactly as recommended by the manufacturer, using 30 μL of lysate 
per well of the GLISA plate. 
For phosphorylation of ERK1/2, lysates prepared as described above were diluted with 4xLDS 
sample buffer (Invitrogen), boiled for 5 minutes, and 12 μL loaded into 12% Bis-Tris NuPAGE gels 
(Invitrogen).  Following electrophoresis on 12% NuPage Bis-Tris gels (Invitrogen), Western blot using a 
mouse anti-pERK1/2 antibody (Cell Signaling) at a dilution of, and a rabbit anti-beta-tubulin antibody 
(AbCam) as loading control.  Secondary detection was done using a goat anti-rabbit 800 and goat anti-
mouse 680LT antibodies (LiCor).  Blots were analyzed using a Odyssey Imager (LiCor) 
Subcellular localization assays 
HeLa cells were plated in 60 mm glass slide-bottomed plates at 4 x 104 cells per plate.  24 hours 
later, cells were treated for 1 hour with 500 nM of the appropriate protein diluted in serum-free DMEM. 
Following incubation, cells were washed three times with PBS + 20 U/mL heparin to remove 
extracellular protein.  Cells were incubated a further 4 hours in serum-containing DMEM + 20 U/mL 
heparin to allow endocytosed proteins to reach a trafficking endpoint.  Cells were treated with either 
LysoTracker RED or LysoTracker GREEN (Invitrogen), at a concentration of 75 nM for the final 30 
minutes of the 4 hour incubation to label lysosomes.  Following incubation, media was aspirated and cells 
were washed once with PBS + 20 U/mL heparin, before replating fresh serum-containing media + 20 
U/mL heparin. 
Cells were imaged at the HCBI (Harvard University) on an LSM 510 confocal microscope (Zeiss) 
using 530/20 and 620/40 filters.  15 individual cells per treatment were photographed.  TIFF images were 63 
 
analyzed with ImageJ using the WCIF-ImageJ Collection (Wright Cell Imaging Center) using default 
parameters.   
Surface charge density analysis 
After stripping the crystal structure of superfolder GFP (PDB Code 2B3P) of all water molecules 
and non-protein atomic coordinates, hydrogen atoms were assigned to the structure by the Visual 
Molecular Dynamics protein visualization package and then minimized in 100 steps of steepest descent 
structure minimization in the NAMD molecular dynamics package using generalized born electrostatics 
and the CHARMM force field, with only the installed hydrogens allowed to vary.  This optimized 
structure was then used for all subsequent analyses.   
Peptide structures were initially generated using the Molefacture tool in VMD, and then 
equilibrated by a 1 ns molecular dynamics simulation using the NAMD molecular dynamics package at 
310 K using generalized born implicit solvation and the CHARMM force field.  A snapshot of the protein 
structure was then taken every 100 ps of a 9 ns molecular dynamics simulation and structurally aligned to 
generate a structural ensemble of each peptide.  These structures were then overlaid and their voltage 
expectation values calculated as described below, with a single modification: after calculation of the 
voltage expectation value 〈𝑉〉 and square-voltage expectation value 〈𝑉2〉, each value was normalized to 
the number of structures in the ensemble to generate approximations of 〈𝑉〉 and 〈𝑉2〉 which take into 
account the intrinsic flexibility of these structures. 
To determine the overall charge density of a supercharged protein sequence, the protein was first 
reduced to a point cloud representation.  From this the convex hull, Γ of the sfGFP protein structure was 
determined using the TetGen tetrahedral mesh generator package in Mathematica, as was the protein 
center of mass, ρ.  The expanded convex hull Γ’ was then generated by radially expanding each point of Γ 
by 5 Å from ρ ( 𝗤′ = {∀𝗾𝜖𝗤:𝗾′ ⃑⃑⃑  = ?   +
𝗾 ⃑ ⃑ −𝜌 ⃑ ⃑ 
‖𝗾 ⃑ ⃑ −𝜌 ⃑ ⃑ ‖(‖𝗾   − ?  ‖ + 5)} ).  Each backbone atom was then assigned a 
charge according to the canonical partial charges of backbone atoms in a peptide chain (N-H 0.2, N-H -
0.2, C=O 0.42, C=O -0.42).  Charged residues were assumed to have charge isotropically distributed 64 
 
around their Cα atoms, and so each residue was treated as a point charge centered at their respective Cα 
coordinate.  The electrical potential function V was then given by: 
𝑉(𝑥  ) =
1
4?𝜀𝜀0
 ∑
?𝑖
‖? 𝑖 ⃑ ⃑  − 𝑥  ‖
𝑁
𝑖=1
 
Where ?  𝑖 is the atomic coordinate of the i-th charged atom, ?𝑖 is its charge, 𝜀 is the permittivity of the 
medium in question (here, 𝜀=81 for liquid water) and 𝜀0 is the permittivity of the vacuum.  The 
expectation value for voltage 〈𝑉〉 and its square 〈𝑉2〉  over Γ’ were then computed by the integrals 
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And the standard deviation of this expectation value was then computed using the relation 
𝜎𝑉
2 = 〈𝑉2〉 − 〈𝑉〉2 
Treatment of cells for high-throughput confocal microscopy 
  96-well    clear  black  flat-bottom  polystyrene  plates  were  purchased  from  Greiner-bio-one; 
Transferrin-Alexa 647 and EGF-Alexa 555 were purchased from Invitrogen.  Rabbit polyclonal anti-
EEA1 was previously described; mouse monoclonal anti-LAMP1 was purchased from BD Pharmingen.  
All  fluorochrome-labeled  secondary  antibodies  were  purchased  from  Invitrogen.  CO2-independent 
medium was purchased from Invitrogen. 
  HeLa cells grown in 96-well plates were incubated at different time intervals with 500 nM of 
+36GFP, +15 GFP, TAT-mCherry, Pen-mCherry or (KKR)9KRR-Cherry at 37 °C in CO2-independent 
medium for up to two hours prior to washing with 20 U/mL heparin in PBS and fixation with 4% PFA.  
Afterwards, cells were permeabilized with saponin (PBS, 0.1% saponin, 4% fish cold gelatin) and stained 
with  antibodies  against  EEA1  and  LAMP1.    The  antigens  were  detected  with  the  appropriate 
fluorophore–labeled  secondary  antibodies.    Cells  were  stained  with  DAPI  to  identify  nuclei.  All 
treatments were performed in triplicate. 65 
 
HeLa cells grown in 96-well plates were stimulated with either 200 ng/mL EGF-Alexa 555, or 25 
g/mL  Transferrin-Alexa  647,  together  with  different  concentrations  of  +36  GFP,  +15  GFP,  TAT-
mCherry, penetratin-mCherry, or (KKR)9KRR-mCherry (0, 0.1, 0.5, 1, or 2 µM) for 30 minutes at 37 °C 
in CO2-independent medium prior to washing with 20 U/mL heparin in PBS and fixation with 4% PFA.  
Cells were stained with DAPI to identify nuclei.  All treatments were performed in triplicate. 
High-throughput confocal microscopy image acquisition and analysis 
Images were acquired with an automated spinning-disk confocal microscope (OPERA, Evotec  
Technologies-PerkinElmer) with a 40X / 0.9 NA water immersion objective.  GFP and Transferrin-647 
were excited simultaneously with 488 and 635 nm lasers and detected with 520/35 nm and 700/90 nm 
filters, respectively.  mCherry or EGF-Alexa 555 and DAPI were excited simultaneously with 561 and 
405 nm lasers and detected with 605/40 nm and 450/50 nm filters.  One hundred images per time point 
were acquired.  Every image contained on average 20 cells.  To minimize laser variability, all plates were 
acquired on the same imaging session.   
  Image analysis was performed using MotionTracking, a custom image analysis software designed 
by Dr. Kalaidzidis.  Before analysis, images were corrected for uneven field illumination and chromatic 
misalignments  using  reference  images.    For  every  image,  individual  vesicles  in  each  channel  were 
identified by fitting a sum of powered Lorenzian functions whose coefficients describe the features (e.g. 
intracellular position, size,  fluorescent integral  intensity)  of  each  individual  objects.    The  number  of 
vesicles and the total integral intensity were normalized by the cytoplasmic area per frame, to account for 
frame-to-frame variability in the number of cells.  Object-based colocalization was assessed on the basis 
of cross-sectional overlap between two or three channels.  An object scored as colocalized when the total 
overlap was greater than 40% of the main object cross-section.   
To compare the fluorescence intensity of GFP and mCherry in each plate, a solution of 200 nM of 
+36GFP and 200 nM mCherry was acquired using the same imaging settings.  The intensity ratio between 
mCherry and GFP measured from this solution was used to normalize all GFP intensity values.  
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Abstract 
The use of nuclease-based technologies that enable site-directed knockout of genes in 
intact, living cells, has expanded dramatically in recent years.  However, technologies that enable 
highly efficient gene repair and targeted integration are comparably underdeveloped.  Site-
specific recombinase enzymes are an attractive basis for a hypothetical gene replacement and 
and genomic integration technology.  Yet there is currently no recombinase platform that is both 
highly active and readily reprogrammable. To address the limitations of site-specific 
recombinase programmability, we have developed a genetic selection based on the Phage-
Assisted Continuous Evolution (PACE) system, recently developed in our lab, to enable the 
directed evolution of recombinase proteins towards user-definable target sequences.  We have 
established a deletion-based selection, optimized the performance of the system, and validated its 
ability to select library members with desirably altered activities.  Using this system we have 
evolved Cre recombinase to higher activity on its native loxP substrate, and have redirected a 
population of Cre variants towards an asymmetric target site located within the human ROSA26 
“safe harbor” locus.   
Introduction 
The use of genetic modification technologies has increased rapidly in recent years 
following the discovery and development of protein classes with programmable DNA-binding 
specificities.  Engineered Zinc Finger libraries1, TALE arrays2, and most recently the short RNA-
guided CRISPR-derived Cas9 system3, have enabled increasingly facile means of targeting 
arbitrary genomic sequences.  Genetic knockout technologies based on the retargeting of 
nucleases have proven to be a highly effective and general approach, and have even seen 72 
 
application in clinical settings.4  Nuclease-based approaches to genome modification rely on 
endogenous cellular repair processes to mediate the generation of the desired sequence change.5,6  
In most cases, inactivation of a target sequence is all that is required, and nucleases serve very 
well in this capacity.7  Following cleavage of sites within the genome, double strand DNA break 
repair responses are triggered, and through repeated cleavage, error-prone repair pathways, such 
as non-homologous end joining (NHEJ),8 can introduce random insertions or deletions at the 
target site, frequently inactivating the gene of interest.   
Targeted integration and gene repair can also be triggered using this approach, as cells 
can utilize homologous pieces of DNA provided in trans through a process known as homology 
directed repair (HDR)6,9,10, to generate a recombinant, user-defined sequence change.  However, 
HDR rates are generally low, and while the efficiency of integration may currently serve as a 
powerful research tool, higher and more reliable integration rates may be needed for application 
of gene correction in therapeutic settings.   
HDR rates vary greatly between cell types, throughout the course of the cell cycle, and 
across the genome5,6.  Indeed, high rates of homologous recombination are only achievable in 
cells artificially stalled during specific high-HDR stages of the cell cycle, or in abnormal cell 
types that exhibit high constitutive rates of homologous recombination6,11,12,10.  Most cells in the 
body are post-mitotic, and exist in a state that has intrinsically low rates of HDR6,13.  While 
methods to augment or stimulate HDR within cells may be developed, it is not clear what impact 
this may have on the physiological state of target cell14, or what unintended rare recombination 
or translocation events it may induce.   73 
 
One potential way to circumvent the stochasticity of HDR, and the potential danger of 
augmenting it globally, is the use of site-specific recombinases.   Recombinases directly catalyze 
strand exchange and ligation between DNA molecules, offering an approach to efficient genomic 
integration.  Due to the catalytic mechanism of many recombinases, including the widely used 
tyrosine recombinases Cre and Flp, induce less DNA damage and toxicity than similarly 
expressed nucleases. These enzymes are covalently linked the to the DNA backbone via a 
phospotyrosine during catalysis, and hold the freed 3’OH ends entirely within the recombinase 
tetrameric complex (Figure 3.1), inaccessible to cellular DNA damage sensors.15  While high 
level and long term expression of recombinases has been been found to have undesireable effects 
on genome stability,16 if used transiently as is the practice with site-directed nucleases, such 
toxicity may be avoided.   
 
Figure 3.1 Mechanism of recombinase catalyzed strand exchange.  The enzyme must assemble as a 
tetramer before any strand cleavage can occur, so off-target events are comparatively rare.  There is never 
a double-strand break and free ssDNA ends are held within the complex during the reaction, minimizing 
DNA damage responses. 
 
Despite their potential, recombinases as a class are underdeveloped since most site-
specific recombinases are not easily reprogrammable.  The most highly active recombinases 
display a complex arrangement of DNA-binding and protein-protein contacts spread throughout 74 
 
their structure (Figure 3.2),17,18 and are consequently not amenable to simple truncation and 
translational fusion to more programmable DNA-binding domains.   
Previous attempts at evolving recombinases have yielded enzymes with low activity,19 or 
have required hundreds of rounds to achieve modest levels of retargeting.20 To address this 
problem, we developed a genetic selection based on the Phage-Assisted Continuous Evolution  
 
Figure 3.2 Recombinase complex assembly. Recombinases monomers (in this case, Cre) shown in 
green and purple bind to DNA over an extended surface area spread across both domains of the protein.  
Both N- and C-terminal lobes of the protein participate in dimerization interactions, as well (unpictured) 
tetramerization. 
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(PACE) system,21 to enable the rapid evolution of recombinase proteins towards targets of 
interest.  Using Cre recombinase as a model, the PACE system was optimized, validated, and 
used to evolve Cre variants with higher activity on their native loxP target site, as well as altered 
specificity towards a human genomic sequence within the hROSA26 locus.22 
Results 
PACE operates by linking the survival of desired functional genetic sequences to the 
filamentous phage life cycle.  The system relies on the essential activity of the filamentous phage 
gene III which functions during both initial infection of host cells, and secretion of progeny 
phage from an infected host.23  The entire selection takes place within a continuous flow 
apparatus, which we have currently adapted and simplified from previously published sytems 
(Figure 3.3).21,24  A chemostat, receiving a constant influx of fresh media, sustains a  constantly 
replicating population of uninfected host cells throughout the course of each PACE experiment.  
Cells from this chemostat are flowed into a separate vessel, termed the cellstat, where a 
population of phage particles reside, each carrying a copy of a ‘selection phagemid’ SP.  Phage 
capable of infecting the host cells and activating expression of phage gene III from a so-called 
‘accessory plasmid’ (AP) are able to produce infectious progeny that are secreted from the host 
cell and reinitiate the process on a fresh host cell.  Phage that are incapable of eliciting gIII 
expression from the AP produce fewer or no progeny and will be diluted away under continuous 
flow.  The flow rate in the cellstat is set such that there is no net-growth of host cells as their 
residence time is shorter than the average bacterial replication cycle.  As the phage life cycle can 
be as short as 15 minutes, the only genetic material actively propagating within the system is that 
of the SP.  This short cycle allows for dozens of rounds of selection, mutagenesis, and 76 
 
amplification to happen in a single 24 hour period, potentially exploring more variants than 
traditional manual iterative directed evolution, and reaching more distant mutated states. 
This cycling process takes place under mutagenesis, driven by a ‘mutagenesis plasmid’ 
(MP) that is induced upon entry into the cellstat to express mutagenic gene products.  The MP 
carries three genes that augment mutagenic rate within the cells.  A dominant negative form of 
the E. coli DNA polymerase proof-reading subunit dnaQ increases base misincorporation during 
phage genome replication.25 Dam methylase is overexpressed to hypermethylate newly 
synthesized DNA and prevent the cell from discriminating parent strand from daughter strand 
during mismatch repair.  Finally, the φ29 phage-derived protein p56 inhibits uracil DNA 
glycosylase,26 resulting in an increase in CT transitions. 77 
 
 
Figure 3.3 Phage-Assisted Continuous Evolution. The function of an evolving gene of interest is linked 
to the phage life cycle by having the gene encoded on the selection phagemid (SP) carryout an activity 
that elicits downstream gIII expression from an engineered accessory plasmid (AP).  A mutagenesis 
plasmid (MP) provides constant mutagenesis.  Active variants surive dilution relative to inactive variants. 
 
 
 
  To establish a recombinase-based genetic reporter system, we chose the tyrosine 
recombinase Cre as a model around which to develop the selection.  Cre is an ideal candidate due 
to the wealth of biochemical and structural information available,17,27 and it is among the most 
used, and most highly active recombianses in biological research.  Cre binds to a specific 34-bp 
DNA sequence, called LoxP, and catalyzes recombination in a manner that is controlled by 78 
 
religation of nicked strands post-exchange depending on specific hybridization of non-
palindromic sticky ends within the recombination complex (Figure 3.4).  This directional 
sequence, flanked by inverted repeats of monomeric Cre binding sites, is what determines the 
outcome of any given recombination reaction.27,28 
   
 
Figure 3.4 Directionality of Cre recombination is controlled by the hybridization and relegation of the 
core sequence.  Cre nicks the core sequence on either side resulting in a 6 base 5’ overhang that must 
anneal prior to ligation of exchanged strands.  The orientation of this core sequences is what gives a LoxP 
binding site directionality, and this controls the progression and direction of recombination. 
 
 
  We assessed the effect of Cre-induced recombination on the expression of a luciferase 
reporter gene within either inversion or deletion based constructs.  Inversion-based reporters 79 
 
were constructed with a the luciferase coding sequence cloned in an inverted orientation relative 
to the upstream promoter, flanked by two inverted loxP sites. Deletion-based reporters were 
constructed by placing a strong transcriptional terminator flanked direct repeats of by loxP sites 
upstream of luciferase.  In both constructs, expression through the recombination cassette was 
driven by an IPTG-regulated promoter, while Cre expression from a separate plasmid was driven 
by a tetracycline-regulated promoter.   
  We found that upon induction of expression through the recombination cassette, 
inversion-based reporters showed as much as 50% lower recombination rates over time (Figure 
3.5a).  This may be due to continued interaction between transcriptional machinery and 
recombination complexes, as the inversion reaction is completely reversible and equilibrates 
between inverted orientations.  An alternative explanation involves expression of long antisense 
mRNA in the inverted orientation, which may interfere with expression o the luciferase reporter 
gene. Deletion based reporters showed a much lower effect of expression through the 
recombination cassette.  This result was reflected in the level of luciferase signal produced by 
either deletion or inversion-based reporters (Figure 3.5b), with deletion reporters showing an 
increased signal concomitant with increased recombination over the same period of time (Figure 
M2.2A), while inversion reporters hit a ceiling of low activity after 3 hours, never reaching the 
level of activity seen with the deletion reporter.  Given that rounds of PACE selection happen on 
the order of  minutes, a reporter which manifests higher gene expression signals more quickly is 
the more desirable configuration.  For this reason, we have used deletion-based reporters in all 
subsequent work. 80 
 
 
Figure 3.5 Performance of Cre inversion and deletion reporters. (a) interaction of gene expression an 
recombination on deletion- and inversion-based reporters, as measured by quantitation of a PCR-based 
gel electrophoresis assay of recombinant plasmids. (b) fold luminescence signal over uninduced controls 
for both deletion and inversion reporters.  The positive control shown is the signal of a pre-deleted 
reporter plasmid derived from the deletion reporter. 
 
 
   Deletion AP constructs were prepared with the phage-shock promoter (PSP) upstream of 
a deletion cassette containing the rrnB transcriptional terminator flanked by loxP sites, with gene 
III and luciferase downstream (Figure 3.6).  Infection with phage induces transcription from the 
PSP, which is terminated until recombinase-mediated deletion of rrnB enables expression of the 
downstream translationally-coupled gene III and luciferase reporters. 
  Cre-containing SP (Cre-SP) constructs were prepared and found to support activity-
dependent phage production from recipient cells carrying the deletion AP in discrete overnight 
phage plaque assays.  Based on this, we attempted continuous propagation across a range of 
dilution rates, and found that Cre-SP maintaining itself under continuous dilution rates as high as  81 
 
 
Figure 3.6 Layout of the Cre deletion-dependent AP construct.  An rrnB terminator flanked by 
directed repeats of LoxP is positioned between the PSP and the gIII coding sequence.  Successful deletion 
results in expression of gIII from the AP, leading to phage propagation. 
 
 
Figure 3.7 Continuous propagation of Cre-SP phage.  Phage carrying Cre-SP, but not negative control 
T7 RNAP-SP, are capable of propagating and inducing coupled luciferase expression on deletion-
dependent LoxP AP host cells at 2 vol/hr. 
 
 
2 volumes per hour (Figure 3.7), comparable to our previously demonstrated T7 RNAP-bearing 
SPs which survive several days at 2 volumes per hour (vol/hr), but fail to propagate at 3 vol/hr, 
suggesting that Cre-SP may be similarly evolved within PACE.   82 
 
  Next, we performed a mock selection experiment by infecting a continuous culture of 
deletion AP-bearing recipient cells with a phage in a 1,000,000:1 ratio of negative control phage 
to Cre-SP phage. By 12 hours post-infection, Cre-SP had come to dominate the cellstat, with 
titers of ~108 pfu/mL, and propagating phage population converted completely to Cre-SP, with 
no detectable control phage present, as analyzed by a gel electrophoresis-based assay (Figure 
3.8). 
 
Figure 3.8 Mock enrichment of functional SP from an excess of non-functional SPs. PCR-based 
detection and gel electrophoresis of from the indicated phage populations and culture supernatants.  
PACE selection enriches Cre-SP from a  1:1x106 SP mixture in 12 hr. 
 
  We validated the ability of the system to arrive at working Cre variants from a starting  
catalytically inactive mutant clone (K201N).29  Following 24 hours of propagation and 
mutagenesis with gIII freely provided on an expression plasmid  (a process referred to as 
‘drift’)21,24 to allow phage survival from an initially inactive starting point, the phage population 83 
 
was transferred to a new cellstat containing loxP.deletion AP host cells.  After 24 hours, a 
population of functional Cre SPs had come to occupy the cellstat.  Sequencing revealed that all 
clones had mutations at the inactivated position, most restoring the wild type residue, but others 
choosing an alternative (K201D).  Luciferase activity assays showed that all surviving variants 
were active, whereas the starting variant was not (Figure 3.9).  
 
Figure 3.9 Mutagenesis and rescue of active variants from an inactive clonal starting point. 24 hours 
of drift followed by 24 hours of LoxP deletion selection resulted in the isolation of a mixed population of 
active variants. 
 
 
  As an initial target of Cre evolution, we identified several loxP-like sequences within the 
human ROSA26 locus22 to evolve altered specificity towards (Figure 3.10).  One of these 
sequences, designated ROSALoxP-7, was identified as having the fewest substitutions at 84 
 
positions within the LoxP site known to be most important for Cre binding27,30  and would thus 
be a potentially feasible target to reach.   
 
Figure 3.10 LoxP-like sequences within the human ROSA26 locus. Sequences found within the human 
ROSA26 locus with the fewest mutations from wild-type LoxP.  Sequence 7 (‘ROSALoxP-7’) was 
chosen for a target due to the minimal number of base substitutions at sites of important protein:DNA 
contanct.  In the top ‘wt’ line, the bold underlined positions correspond to the most important structural 
contacts.  Red positions are substitutions away from the wild-type LoxP sequence. 
 
 
  As the ROSALoxP-7 sequence is asymmetric, we chose to split the evolution into two 
paths, one to evolved specificity of the left half-site and core sequences, and the other for the 
right half-site and core sequences (Figure 3.11).  The resulting enzymes, active on their 
respective symmetric LoxP-like sites, would then be used as a heterodimer against the full 
asymmetric site.  Given previous demonstrations of heterodimeric function of engineered Cre 
and other tyrosine recombinases, we expect our evolution strategy to be feasible.20,31 
 85 
 
 
 
Figure 3.11 progression of evolutionary intermediate target sites for the left and right arcs towards 
ROSALoxP-7. Each evolutionary arc is split into four intermediates, substituting a single important 
structural contact (and additional less essential positions) at each step.  Colors correspond to the stage at 
which the substitution is introduced. 
 
 
  Thus far we have carried forward the left arc of the ROSALoxP-7 evolution successfully 
through step 3 (7L3). At each step, the surviving population of SPs are passaged forward to 
initiate the evolution, which proceeds through a period of propagation on the current AP, a 
period of 1:1 mixing of two host cell AP populations in the cellstat, followed by a final 
propagation on the next AP alone.    As of step 7L3, all clones have detectable activity on 7L3 
APs, where wild-type Cre does not (Figure 3.12).  Though the mixing transition strategy proved 
necessary for progression of the selection, one probably consequence of this is that promiscuous 86 
 
variants dominate the population.  This can be seen in the moderate but broad activity of the 
clones subjected to deletion-dependent luciferase assays in Figure 3.12.  All clones retain 
activity on prior evolutionary intermediate target sequences. 
 
Figure 3.12 Activity of ROSAloxP-7L arc evolved population.  All clones have gained appreciable 
activity on the 7L3 AP target, but retained promiscuity on prior intermediates. 
 
 
  Sequencing of phage clones has revealed the population converging on a number of 
consensus mutation positions.  The 7L3-selected SP clones all contained 5 consensus mutations 
(M44V, A53E, A249V, R259C, and E262A), in addition to 1-3 non-shared coding mutations per 
clone.  These 5 mutations are located within helices involved in protein:DNA contacts within the 
Cre recombinase crystal structure (Figure 3.13), and 3 of these mutations appear to be involved 
in direct contacts with the bases substituted in the mutated ROSALoxP intermediate DNA 
sequence (Figure 3.14).   87 
 
 
Figure 3.13 Converged mutations from the ROSAloxP-7L3 evolution map to helices and positions 
involved in DNA-binding and protein-protein interactions.  Consensus positions in the 7L3 evolved 
population include M44V, A53E, A249V, E262A, R259C. 
 
 
Figure 3.14 Three consensus positions make direct contact with substituted target base positions. 
Converged positions M44V, R259C, and E262A make direct contacts with substituted target bases. 88 
 
We have also initiated evolution of Cre towards the right arc of the ROSALoxP-7 
evolution, and have evolved a population in the same fashion as the left arc up through the 
intermediate target 7R2 (Figure 3.11).  Once again, the population shows moderate levels of, 
broad deletion-dependent luciferase reporter activity on all intermediate sequences it has been 
exposed to, and have notably higher activity than the otherwise inactive wild-type Cre on these 
intermediate target sequences (Figure 3.15).  Some clones show weak activity on 7L3 as well, 
suggesting that the next intermediate evolution has some viable starting activity.  Sequencing of 
7R2-evolved clones reveals a pattern of mutations similar to that of the 7L3 clones, with 
mutations present both at the site of protein-protein interactions and specific substituted base 
contacts (Figure 3.16).  Consensus positions at E262G, I306V, I320M is common across almost 
all clones.   Among the converged positions, only the E262 position can be seen as making a  
   
Figure 3.15 Activity of 7R2-evolved clones. All clones have gained appreciable activity on the 7R2 AP 
target, but retained promiscuity on prior intermediates. 89 
 
 
Figure 3.16 Consensus mutations in the ROSALoxP7-R arc as of 7R3.  Converged positions at 
E262G, I306V, and I320M and additional repeating substitutions at I166V, T286A, and G342S 
 
 
direct contact with one of the mutated target bases (Figure 3.16), and two distinct mutations  
(E262G/A GAA->GGA or ->GCA) appear to have arisen independently, suggesting a central 
role for this position in operating on the mutated R2 target sequence.  Other converged positions 
are either internal to the protein (I306V), or located on a dimerization interface (I320M).  Among 
the population containing the core triple-mutant set, there are some common and repeated, 
though not yet converged mutations, including I166V which can be seen to make contact with 
one of the target DNA bases.  Finally, a large number of non-repeating mutations are located in 
the helices in the N-terminal half of the protein (the lower portion of the protein in Figure 3.16) 
that contact mutated bases in the target sequence.  Together, this pattern of mutations suggests 
that our 7R arc evolution is selecting for Cre variants with functional changes at the DNA-
binding interface, and not merely enhancing dimerization interactions or protein folding. 90 
 
   
Finally, we have evolved Cre enzymes with apparent higher recombination rates in E. 
coli on the wild type loxP sequence.  While Cre-based deletion is currently a powerful tool in 
basic research, synthetic biology, and circular DNA vector development, issues with the speed, 
efficiency, and occurrence of non-deletion side-reactions make the use of Cre less than ideal.  
For example, faster and more efficient Cre deletion variants may achieve higher knockout 
efficiency in ‘floxed’ transgenic mouse lines, resulting in more uniform conversion within the 
population of Cre-expressing cells.  A faster Cre may improve dynamics in recombinase-
dependent synthetic biological memory and counting applications32.  Cre variants evolved to be 
more effective at deleting DNA between loxP sites maybe enable higher production yields of 
prokaryotic sequence-free minicircle DNA for use in DNA vaccines and episomal transgenesis.33  
Towards these goals, we evolved more active Cre variants by propagating Cre 
recombinase on wild type loxP deletion APs and increasing the flow rate 0.5 vol/hr every 24 
hours until reaching a rate of 4 vol/hr.   Whereas wildtype Cre fails to propagate in PACE at 
dilution rates higher than 2.5 vol/hr (and shows a 100-fold drop in titer compared to 2 vol/hr), we 
successfully evolved a Cre population capable of maintaining itself at high titers (~108 pfu/mL) 
for over 24 hours at 4 vol/hr.  Sequencing of surviving phage showed evidence of some sequence 
convergence, and the most common mutations (multiple unique substitutions of A285 to D, V or 
T, as well as a reoccurring triple mutant M31I/E151G/G281D) were located either internally, 
possibly affecting internal packing of the protein and dynamics during recombination, or on 
surface areas involved in protein-protein interactions between Cre monomers.   Characterization 
of the activity of these enhanced Cre variants is the subject of future and ongoing research. 91 
 
 
 
Discussion 
  Given the above progress on Cre evolution using the PACE recombinase system, we plan 
to continue evolution of towards the human ROSA26 integration target sequence.  The 
promiscuity of the 7L3 and 7R2-evolved populations is of great concern if the evolved 
ROSALoxP-7 heterodimer pair is to be used effectively.  To this end, we will be initiating 
negative selections against previous intermediate target sequences using the recently published 
negative selection system that makes use of a dominant-negative form of gIII to delivery a 
tunable fitness cost to variants displaying broad activity profiles. 
Methods 
PACE apparatus setup 
  The PACE apparatus used in this work is a derivation of the previously published 
chemostat-based (versus turbidostat) PACE system with custom modifications.21,24  A 150 mL 
Erlenmeyer flask (VWR) is used for the chemostat rather than a 500 mL bioreactor vessel 
(Belco).  The flask is stoppered with a 19/22 mm rubber septum.  Media, vent, pressure, waste, 
and cellstat-out lines are serviced with disposable 22 ga and 16 ga 4 inch veterinary needles 
(AirTite).  All connection tubing is 1/16 inch inner diameter clear PVC tubing.  Cellstats are 
made with 50 mL Erlenmeyer flasks sealed with 14/22 mm rubber septa.  Chemostat is 
maintained at 100 mL throughout the course of each experiment.  All cellstats are run at 20 mL 
when propagating phage on single AP populations and 40 mL when propagating on mixed APs.   92 
 
Mutagenesis and recombinant cheater control 
  Mutagenesis is induced from MPs using 5 mM final concentration arabinose drip from a 
syringe pump.  The cellstats are maintained under 5 µg/mL kanamycin to combat the generation 
of recombinant cheater phage, which commonly recombine gIII into the SP using the upstream 
KanR gene for a 5’ junction. 
Accessory Plasmid cloning 
  Cloning of AP variants was performed using restriction digest of a PCR product of the 
p175dc wild-type LoxP deletion AP with XhoI and NheI.  PCR of the terminator deletion 
cassette with compatible primers generating an insert containing one full LoxP variant site at the 
3’ end of the terminator cassette, and the vector containing the paired LoxP site on the 5’ end of 
the deletion cassette insertion site.  All PCRs are digested for 1 hour, cleaned using Qiagen PCR 
cleanup kit, ligated for 10 minutes using the Quick Ligation kit (NEB), and transformed into 
Mach1 chemically competent cells (Life Technologies). 
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Abstract 
Programmable site-specific endonucleases have proven to be useful tools for genome 
editing and may lead to novel therapeutics to treat genetic diseases.  Cas9 cleaves double-
stranded DNA in a variety of organisms at a sequence programmed by a short single-guide RNA 
(sgRNA).  The specificity of Cas9-mediated DNA cleavage is imperfect, and off-target cleavage 
both in the test tube and in cells has been observed.1–5  Recently engineered variants of Cas9 that 
cleave only one DNA strand (“nickases”) enable double-stranded breaks to be specified by two 
distinct sgRNA sequences,5–7 but still suffer from off-target cleavage activity7,8 arising from the 
ability of each monomeric nickase to remain active when individually bound to DNA.9–11  Here 
we describe the development of a FokI nuclease fusion to a catalytically dead Cas9 that requires 
simultaneous DNA binding and association of two FokI-dCas9 monomers to cleave DNA.  Off-
target DNA cleavage of the engineered FokI-dCas9 (fCas9) is further reduced by the requirement 
that only sites flanked by two sgRNAs ~15 or 25 base pairs apart are cleaved, a much more 
stringent spacing requirement than nickases.  In human cells, fCas9 modified target DNA sites 
with efficiency comparable to that of nickases and with > 140-fold higher specificity than wild-
type Cas9.  At loci with highly similar off-target sites, fCas9 modified genomic DNA in human 
cells with greater specificity than Cas9 nickases.  Target sites that conform to the substrate 
requirements of fCas9 are abundant in the human genome, occurring on average once every 34 
bp. 
Introduction   
  The recent development of robust, predictable, and user-friendly methods for the 
generation of sequence-specific DNA-binding proteins has led to a rapid expansion of the field 97 
 
of genome editing.  Today, user-defined site-specific genome modification has become a 
powerful tool in biological research12, and holds significant potential to serve as the basis of a 
new generation of human therapeutics13 (NCT00842634, NCT01044654, NCT01252641). 
 
Figure 4.1 Architecture of Cas9.  (a) Cas9 protein (yellow) binds to target DNA in complex with a 
guide RNA (sgRNA, green).  The S. pyogenes Cas9 protein recognizes the PAM sequence NGG (blue), 
initiating unwinding of dsDNA and sgRNA:DNA base pairing. 
 
One such programmable endonuclease system uses the CRISPR-derived Cas9 nuclease 
complexed with an engineered single-guide RNA (sgRNA) to target dsDNA sequences for 
cleavage (Figure 4.1).10  The 3’ end of the sgRNA forms a scaffold that binds Cas9 protein,14 
while the 5’ most ~17 to 20 bases8 of the sgRNA pair with the target DNA to determine DNA 
cleavage specificity. Provided that the target sequence is adjacent to a short 3’ motif, the 
protospacer adjacent motif (PAM) required for initial binding and Cas9 activation10 (Figure 4.1), 
any DNA locus can in principle be targeted.  In cells, Cas9:sgRNA-induced double strand breaks 
can result in functional gene knockout through non-homologous end joining (NHEJ) or alteration 
of a target locus to virtually any sequence through homology-directed repair (HDR) with an 98 
 
exogenous DNA template.9,14,15  Cas9 is an especially convenient genome editing platform,16 as a 
genome editing agent for each new target site of interest can be accessed by simply generating 
the corresponding sgRNA. This approach has been widely used to create targeted knockouts and 
gene insertions in cells and model organisms, and has also been recognized for its potential 
therapeutic relevance. 
  While Cas9:sgRNA systems provide a high level of programmability and ease of use, our 
group1 and others2–5 have reported the ability of Cas9 to cleave off-target genomic sites, resulting 
in modification of unintended loci that can limit the usefulness of Cas9 as a research tool and as 
a potential therapeutic.  We hypothesized that engineering Cas9 variants to cleave DNA only 
when two simultaneous, adjacent Cas9:DNA binding events take place could substantially 
improve genome editing specificity since the likelihood of two adjacent off-target binding events 
is much smaller than the likelihood of a single off-target binding event (approximately 1/n2 vs. 
1/n).  Such an approach is distinct from the recent development of mutant Cas9 proteins that 
cleave only a single strand of dsDNA (“nickases”).  Nickases can be used to nick opposite 
strands of two nearby target sites, generating what is effectively a double strand break, and 
paired Cas9 nickases can effect substantial on-target DNA modification with reduced off-target 
modification.5,7,8  Because each of the component Cas9 nickases remains catalytically active9–11 
and single-stranded DNA cleavage events are weakly mutagenic,17,18 nickases can induce 
genomic modification even when acting as monomers.5,6,14  Indeed, Cas9 nickases have been 
previously reported to induce off-target modifications in cells.7,8  Moreover, since paired Cas9 
nickases can efficiently induce dsDNA cleavage-derived modification events when bound up to 
~100 bp apart,6,7 the statistical number of potential off-target sites for paired nickases is larger 
than that of a more spatially constrained dimeric Cas9 cleavage system. 99 
 
  To further improve the specificity of the Cas9:sgRNA system, we sought to engineer an 
obligate dimeric Cas9 system analogous to previously developed dimeric zinc-finger nucleases 
(ZFNs) and TALENs.  These nucleases have been widely used as research tools in cell culture 
and in vivo19, and ZFNs are currently in clinical trials as potential human therapeutics.13  Based 
on ZFN and TALEN examples, we speculated that fusing the FokI restriction endonuclease 
cleavage domain to a catalytically dead Cas9 (dCas9) could create an obligate dimeric Cas9 that 
would cleave DNA only when two distinct FokI-dCas9:sgRNA complexes bind to adjacent sites 
(“half-sites”) with particular spacing constraints (Figure 4.2).   
 
Figure 4.2 Architecture FokI-dCas9 fusion variants. Monomers of FokI nuclease (red) fused to dCas9 
bind to separate sites within the target locus.  Only adjacently bound FokI-dCas9 monomers can assemble 
a catalytically active FokI nuclease dimer, triggering dsDNA cleavage. 
 
In contrast with Cas9 nickases, in which single-stranded DNA cleavage by monomers 
takes place independently, the DNA cleavage of FokI-dCas9 requires simultaneous binding of 
two distinct FokI-dCas9 monomers because monomeric FokI nuclease domains are not 
catalytically competent.20  In principle this approach should increase the specificity of DNA 
cleavage relative to wild-type Cas9 by doubling the number of specified target bases contributed 100 
 
by both monomers of the FokI-dCas9 dimer, and should also offer improved specificity 
compared to nickases due to inactivity of monomeric FokI-dCas9:sgRNA complexes, and due to 
the more stringent spatial requirements for assembly of a FokI-dCas9 dimer. 
Results 
While fusions of Cas9 to short functional peptide tags have been described to enable 
sgRNA-programmed transcriptional regulation,21 to our knowledge no fusions of Cas9 with 
active enzyme domains have been previously reported.  Therefore we began by constructing and 
characterizing a wide variety of FokI-dCas9 fusion proteins with distinct configurations of a 
FokI nuclease domain, dCas9 containing inactivating mutations D10A and H840A, and a nuclear 
localization sequence (NLS).  We fused wild-type, homodimeric, FokI to either the N- or C-
terminus of dCas9, and varied the location of the NLS to be at either terminus or between the 
two domains (Figure 4.3).  We further varied the length of the linker sequence as either one or 
three repeats of Gly-Gly-Ser (GGS) between the FokI and dCas9 domains.   
 
Figure 4.3 FokI-dCas9 fusion architectures tested.  Four distinct configurations of NLS, FokI nuclease, 
and dCas9 were assembled, with the FokI-dCas9 linker varied as either one or three repeats of (Gly-Gly-
Ser) per configuration. 
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Figure 4.4 sgRNA target sites tested within EmGFP.  Target sites were chosen to test FokI-dCas9 
activity either an orientation in which each PAM is distal from the cleaved spacer sequence (orientation 
A), or proximal to the cleaved spacer (orientation B).  Together, these seven sgRNAs enabled testing of 
FokI-dCas9 fusion variants across seven spacer lengths ranging from 5 to 43 bp in orientation A and six 
spacer lengths ranging from 4 to 42 in orientation B. 
 
Since previously developed dimeric nuclease systems are sensitive to the length of the 
spacer sequence between half-sites,22,23 we also tested a wide range of spacer sequence lengths 
between two sgRNA binding sites within a test target gene, Emerald GFP (Life Technologies) 
(referred to hereafter as GFP) (Figure 4.4).  Two sets of sgRNA binding-site pairs with different 102 
 
orientations were chosen within GFP.  One set placed the pair of NGG PAM sequences distal 
from the spacer sequence, with the 5’ end of the sgRNA adjacent to the spacer (orientation A),, 
while the other placed the PAM sequences immediately adjacent to the spacer (orientation B).  In 
total, seven pairs of sgRNAs were suitable for orientation A, and six were suitable for orientation 
B.  By pairwise combination of the sgRNA targets, we tested spacer lengths in both dimer 
orientations, ranging from 5 to 43 bp in orientation A, and 4 to 42 bp in orientation B.  In total, 
216 pairs of FokI-dCas9:sgRNA complexes were generated and tested, exploring four fusion 
architectures, 17 protein linker variants (described below), both sgRNA orientations, and 13 
spacer lengths between half-sites. 
  To assay initially the activities of these candidate FokI-dCas9:sgRNA pairs, we used a 
previously described flow cytometry-based fluorescence assay2,8 in which DNA cleavage and 
NHEJ of a stably integrated constitutively expressed GFP gene in HEK293 cells leads to loss of 
cellular fluorescence (Figure 4.5).  For comparison, we assayed the initial set of FokI-dCas9 
variants side-by-side with the corresponding Cas9 nickases and wild-type Cas9 in the same 
expression plasmid across both sgRNA spacer orientation sets A and B.  Cas9 protein variants 
and sgRNA were generated in cells by transient co-transfection of the corresponding Cas9 
protein expression plasmids together with the appropriate pair of sgRNA expression plasmids.  
The FokI-dCas9 variants, nickases, and wild-type Cas9 all targeted identical DNA sites using 
identical sgRNAs.  While this assay showed a consistent ~5% background signal in the absence 
of sgRNA, it enabled the rapid assessment of many fusion constructs, sgRNA orientations, and 
DNA spacer lengths to identify active constructs for further optimization. 
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Figure 4.5.  GFP disruption assay for measuring genomic DNA-modification activity.  (a) A HEK293-
derived cell line constitutively expressing a genomically integrated EmGFP gene was used to test the 
activity of candidate FokI-dCas9 fusion constructs.  Co-transfection of these cells with appropriate nuclease 
and sgRNA expression plasmids leads to dsDNA cleavage within the EmGFP coding sequence, stimulating 
error-prone NHEJ and generating indels that can disrupt the expression of GFP, leading to loss of cellular 
fluorescence.  The fraction of cells displaying a loss of GFP fluorescence is then quantitated by flow 
cytometry.  (b) Typical epifluorescence microscopy images at 200x magnification of EmGFP-HEK293 
cells before and after co-transfection with wild-type Cas9 and sgRNA expression plasmids. 
 
  Most of the initial FokI-dCas9 fusion variants were inactive or very weakly active 
(Figure 4.6).  The NLS-FokI-dCas9 architecture (listed from N to C terminus), however, 
resulted in a 10% higher frequency of GFP-negative cells above that of the corresponding no-
sgRNA control when used in orientation A, with PAMs distal from the spacer. (Figure 4.6a).  In 
contrast, NLS-FokI-dCas9 activity above background was not detected when used with sgRNA 
pairs in orientation B, with PAMs adjacent to the spacer (Figure 4.6b).  Examination of the 
recently reported Cas9 structures24,25 reveals that the Cas9 N-terminus protrudes from the RuvC 
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domain, which contacts the 5’ end of the sgRNA:DNA duplex.  We speculate that this 
arrangement places an N-terminally fused FokI distal from the PAM, resulting in a preference 
for sgRNA pairs with PAMs distal from the cleaved spacer (orientation A, Figure 4.4).  While 
other FokI-dCas9 fusion pairings and the other sgRNA orientation in some cases showed modest 
activity, we chose NLS-FokI-dCas9 with sgRNAs in orientation A for further development.  
 
Figure 4.6 Activities of FokI-dCas9 fusion candidates on sgRNA pairs of different orientations and 
of varying spacer lengths.  Activity on (a) orientation A sgRNA spacers and (b) orientation B sgRNA 
spacers.  All FokI-dCas9 fusion data shown are the results of single trials.  Wild-type Cas9 and Cas9 
nickase data are the average of two replicates, while the ‘no treatment’ negative control data is the 
average of 6 replicates, with error bars representing one standard deviation.  The gray dotted line across 
the Y-axis corresponds to the average of the ‘no treatment’ controls performed on the same day.   105 
 
  Next we optimized the protein linkers between the NLS and FokI domain, and between 
the FokI domain and dCas9 in the NLS-FokI-dCas9 architecture.  We tested 17 linkers with a 
wide range of amino acid compositions, predicted flexibilities, and lengths varying from 9 to 21 
residues (Figure 4.7).   
 
Figure 4.7 Table of all linker variants tested.  The initial active construct NLS-FokI-dCas9 with a 
(GGS)3 linker between FokI and dCas9 was tested across a range of alternate linkers.  The final choice of 
linkers for fCas9 is highlighted in blue.  Wild-type Cas9 and Cas9 nickase were included for comparison.   
 
Between the FokI domain and dCas9 we identified a flexible 18-residue linker, (GGS)6, 
and a 16-residue “XTEN” linker (FokI-L8 in Figure 4.7) based on a previously reported 
engineered protein with an open, extended conformation,26 as supporting the highest levels of 
genomic GFP modification (Figure 4.8).  The XTEN protein was originally designed to extend 
the serum half-life of translationally fused biologic drugs by increasing their hydrodynamic 
radius, acting as protein-based functional analog to chemical PEGylation.  Since XTEN is 
chemically stable, non-cationic, non-hydrophobic, and predicted to adopt an extended, 106 
 
unstructured conformation, we hypothesized that an XTEN-based linker could functional as a 
stable, inert linker sequence for fusion proteins.  The sequence of the XTEN protein tag from E-
XTEN was analyzed, and repeating motifs within the amino acid sequence were aligned.  The 
sequence used in the FokI-dCas9 fusion construct FokI-L8 (Figure 4.7) was derived from the 
consensus sequence of a common E-XTEN motif, and a 16-residue sequence was chosen from 
within this motif to test as a FokI-dCas9 linker. 
 
Figure 4.8 Optimization of protein linkers in NLS-FokI-dCas9. The activity of FokI-dCas9 fusions with 
linker variants.  Each variant was tested across a range of spacer lengths from 5 to 43 bp using sgRNA pair 
orientation A.  A control lacking sgRNA (grey) was included for each separate fusion construct. 
 
 
Many of the FokI-dCas9 linkers tested including the optimal XTEN linker resulted in 
nucleases with a marked preference for spacer lengths of ~15 and ~25 bp between half-sites, 
with all other spacer lengths, including 20 bp, showing substantially lower activity (Figure 4.8).  
This pattern of linker preference is consistent with a model in which the FokI-dCas9 fusions 
must bind to opposite faces of the DNA double helix to cleave DNA, with optimal binding 107 
 
taking place ~1.5 or 2.5 helical turns apart.  The variation of the NLS-FokI linkers did not 
strongly affect nuclease performance, especially when combined with the XTEN FokI-dCas9 
linker. 
  The NLS-GGS-FokI-XTEN-dCas9 construct consistently exhibited the highest activity 
among the tested candidates, inducing loss of GFP in ~10% of cells over background, compared 
to ~15% and ~25% for Cas9 nickases and wild-type Cas9 nuclease, respectively (Figure 4.9a).  
All subsequent experiments were performed using this construct, hereafter referred to as fCas9.  
To confirm the ability of fCas9 to efficiently modify genomic target sites, we used the T7 
endonuclease I Surveyor assay to measure the amount of mutation at each of seven target sites 
within the integrated GFP gene in HEK293 cells treated with fCas9, Cas9 nickase, or wild-type 
Cas9 and either two distinct sgRNAs in orientation A or no sgRNAs as a negative control.  
Consistent with our flow cytometry-based studies, fCas9 was able to modify the GFP target sites 
with optimal spacer lengths of ~15 or ~25 bp at a rate of ~20%, comparable to the efficiency of 
nickase-induced modification and approximately two-thirds that of wild-type Cas9 (Figure 4.9a-
c).   
  Next we evaluated the ability of the optimized fCas9 to modify 14 distinct endogenous 
genomic loci in five genes by Surveyor assay.  AAVS1 (one site), CLTA (two sites), EMX (two 
sites), HBB (six sites) VEGF (three sites), and were targeted with two sgRNAs per site in 
orientation A spaced at various lengths (Figure 4.10).  Consistent with the results of the 
experiments targeting GFP, at appropriately spaced target half-sites fCas9 induced efficient 
modification of all five genes, ranging from 8% to 22% target chromosomal site modification 
(Figure 4.11a-e).  Among the sgRNA spacer lengths resulting in the highest modification at each 
of the six genes targeted (including GFP), fCas9 induced on average14.9% (± 6.0% s.d.) 108 
 
 
Figure 4.9 GFP gene modification by fCas9, Cas9 nickase, and wild-type Cas9.  (a) GFP disruption 
activity measured by flow cytometry of cells treated transfected with fCas9, Cas9 nickase, or wild-type 
Cas9, with either no sgRNA, or sgRNA pairs of variable spacer length targeting the GFP gene in 
orientation A.  (b) Indel modification efficiency from PAGE analysis of a Surveyor cleavage assay of 
renatured target-site DNA amplified from cells treated with fCas9, Cas9 nickase, or wild-type Cas9 and 
two sgRNAs spaced 14 bp apart targeting the GFP site (sgRNAs G3 and G7; Figure 4.4), each sgRNA 
individually, or no sgRNAs.  The indel modification percentage is shown below each lane for samples 
with modification above the detection limit (~2%).  (c) Indel modification efficiency for treatments 
shown in (a). 
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Figure 4.10 Target DNA sequences in endogenous human AAVS1, CLTA, HBB, EMX, and VEGF 
genes.  sgRNA target sites tested within endogenous human AAVS1, CLTA, HBB, EMX, and VEGF genes.  
Fourteen paired sgRNA target sites were chosen to test the activity of the optimized fCas9 fusion in an 
orientation in which the PAM is distal from the cleaved spacer sequence (orientation A).  Together, these 
14 sgRNA pairs enabled testing of fCas9 fusion variants across twelve spacer lengths ranging from 5 to 
47 bp. 
 
modification, while Cas9 nickase and wild-type Cas9 induced on average 20.6% (± 5.6% s.d.) 
and 28.2% (± 6.2% s.d.) modification, respectively, from their optimal sgRNA pairs for each 
gene.   110 
 
 
Figure 4.11 Genomic DNA modification by fCas9, Cas9 nickase, and wild-type Cas9.  Indel 
modification efficiency as measured by Surveyor assay for target sites within the (c) AAVS1 (e) 
CLTA, (f) EMX, (g) HBB, and (h) VEGF genes.  Error bars reflect standard error of the mean 
from three biological replicates performed on different days.   
 
As the sgRNA requirements of fCas9 potentially restrict the number of potential off-
target substrates of fCas9, we compared the effect of guide RNA orientation on the ability of 
fCas9, Cas9 nickase, and wild-type Cas9 to cleave target GFP sequences.  Consistent with 111 
 
previous reports,5–7 Cas9 nickase efficiently cleaved targets when guide RNAs were bound either 
in orientation A or orientation B, similar to wild-type Cas9 (Figure 4.12a, b).  In contrast, fCas9 
only cleaved the GFP target when guide RNAs were aligned in orientation A (Figure 4.9a-c and 
Figure 4.13a, b).  This orientation requirement further limits opportunities for undesired off-
target DNA cleavage. 
 
Figure 4.12 Dependence of fCas9 on sgRNA pair orientation. (a) GFP gene disruption by wild-type 
Cas9, Cas9 nickase, fCas9 using sgRNA pairs in orientation A.  High activity of fCas9 requires spacer 
lengths of ~15 or 25 bp.  (b) GFP gene disruption using sgRNA pairs in orientation B.  Cas9 nickase, but 
not fCas9, accepts either orientation of sgRNA pairs.  The “no treatment” control refers to cells receiving 
no plasmid DNA.   
 
  Importantly, no modification was observed by GFP disruption or Surveyor assay when 
any of four single sgRNAs were expressed individually with fCas9, as expected since two 
simultaneous binding events are required for FokI activity (Figure 4.9b and Figure 4.13).   In 
contrast, GFP gene disruption resulted from expression of any single sgRNA with wild-type 
Cas9 (as expected) and, in the case of two single sgRNAs, with Cas9 nickase.  High-throughput 112 
 
 
Figure 4.13.  Paired sgRNA dependence of fCas9 compared to Cas9 nickase and wild-type Cas9. 
Indel frequency identified from high-throughput sequencing of GFP on-target sites amplified from 
genomic DNA isolated from human cells treated with a plasmid expressing wild-type Cas9, Cas9 nickase, 
or fCas9; and either a plasmid expressing a single sgRNA (G1, G3, G5, or G7), or two plasmids each 
expressing a different sgRNA (G1+G5 or G3+G7).  As a negative control, transfection and sequencing 
were performed in triplicate as above without any sgRNA expression plasmids.  
 
sequencing to detect indels at the GFP target site in cells treated with a single sgRNA and fCas9, 
Cas9 nickase, or wild-type Cas9 revealed the expected substantial level of modification ranging 
from 2.3% to 14.3% of sequence reads.  Modification by fCas9 in the presence of any of the four 
single sgRNAs was not detected above background (< ~0.03% modification), consistent with the 
requirement of fCas9 to engage two sgRNAs in order to cleave DNA.  In contrast, Cas9 nickases 
in the presence of single sgRNAs resulted in modification levels ranging from 0.05% to 0.16% at 
the target site (Figure 4.13).  The detection of bona fide indels at target sites following Cas9 
nickase treatment with single sgRNAs confirms the mutagenic potential of genomic DNA 
nicking, consistent with previous reports.5,6,14,17,18  These results collectively demonstrate that 113 
 
Cas9 nickase can induce genomic DNA modification in the presence of a single sgRNA, in 
contrast with the absence of single-sgRNA modification by fCas9.  Taken together, these results 
indicate that fCas9 can modify genomic DNA efficiently and in a manner that requires 
simultaneous engagement of two guide RNAs targeting adjacent sites, unlike the ability of wild-
type Cas9 and Cas9 nickase to cleave DNA when bound to a single guide RNA. 
 
Figure 4.14.  fCas9 indel frequency of genomic targets reflects sgRNA pair spacer length 
preference.  The graph shows the relationship between spacer length (number of bp between two 
sgRNAs) and the indel modification efficiency of fCas9 normalized to the indel modification efficiency 
of the same sgRNAs co-expressed with wild-type Cas9 nuclease.  Colored triangles below the X-axis 
denote spacer lengths that were tested but which yielded no detectable indels for the indicated target gene.  
These results suggest that fCas9 requires ~15 bp or ~25 bp between half-sites to efficiency cleave DNA.   
   
The above results collectively reveal much more stringent spacer, sgRNA orientation, 
and guide RNA pairing requirements for fCas9 compared with Cas9 nickase.  In contrast with 
fCas9 (Figure 4.14), Cas9 nickase cleaved sites across all spacers assayed (5- to 47- bp in 
orientation A and 4 to 42 bp in orientation B in this work) (Figures 4.9, 4.12, and 4.13).  These 114 
 
observations are consistent with previous reports of Cas9 nickases modifying sites targeted by 
sgRNAs with spacer lengths up to 100 bp apart.6,7  The more stringent spacer and sgRNA 
orientation requirements of fCas9 compared with Cas9 nickase reduces the number of potential 
genomic off-target sites of the former by approximately 10-fold (Appendix A).  Although the 
more stringent spacer requirements of fCas9 also reduce the number of potential targetable sites, 
sequences that conform to the fCas9 spacer and dual PAM requirements exist in the human 
genome on average once every 34 bp (9.2 x 107 sites in 3.1 x 109 bp) (Appendix A).  We also 
anticipate that the growing number of Cas9 homologs with different PAM specificities28 will 
further increase the number of targetable sites using the fCas9 approach. 
  To evaluate the DNA cleavage specificity of fCas9, we measured the modification of 
known Cas9 off-target sites of CLTA, EMX, and VEGF genomic target sites.1,2,7,8  The target site 
and its corresponding known off-target sites (Appendix B) were amplified from genomic DNA 
isolated from HEK293 cells treated with fCas9, Cas9 nickase, or wild-type Cas9 and two 
sgRNAs spaced 19 bp apart targeting the CLTA site, two sgRNAs spaced 23 bp apart targeting 
the EMX site, two sgRNAs spaced 14 bp apart targeting the VEGF site, or two sgRNAs targeting 
an unrelated site (GFP) as a negative control.  In total 11 off-target sites were analyzed by high-
throughput sequencing (Figure 4.15a-d).  Sequences containing insertions or deletions of two or 
more base pairs in potential genomic off-target sites and present in significantly greater numbers 
(P value < 0.005, Fisher’s exact test) in the target sgRNA-treated samples versus the control 
sgRNA-treated samples were considered Cas9 nuclease-induced genome modifications.  For 10 
of the 11 off-target sites assayed, fCas9 did not result in any detectable genomic off-target 
modification within the sensitivity limit of our assay (< 0.002%, see Methods), while 115 
 
demonstrating substantial on-target modification efficiencies of 5% to 10% (Figure 4.15a-c and 
Appendix C)    
 
Figure 4.15 Off-target indel mutation frequency induced by fCas9, Cas9 nickase, or wild-type Cas9. 
Indels identified via high-throughput DNA sequencing of amplified genomic on-target sites and off-target 
sites from human cells treated with fCas9, Cas9 nickase, or wild-type Cas9. (a) CLTA site (sgRNAs C1 
and C2), (c) EMX site (sgRNAs E1 and E2), or (d, e) VEGF site (sgRNAs V1 and V2). In (a-d), all 
significant (P value < 0.005 Fisher’s Exact Test) indel frequencies are shown.   116 
 
The detailed inspection of fCas9-modified VEGF on-target sequences (Figure 4.16) 
revealed a prevalence of deletions ranging from two to dozens of base pairs consistent with 
cleavage occurring in the DNA spacer between the two target binding sites. For each target site 
at CLTA, EMX, and VEGF, fCas9 predominantly induces deletions with insertions representing < 
5% of all modifications.  This prevalence of deletions is also observed with TALENs, which 
have similar spacer length preferences.29   
 
Figure 4.16 Examples of modified sequences at the VEGF on-target site with fCas9.  The unmodified 
genomic site is the first sequence, followed by the top eight sequences containing deletions. The numbers 
before each sequence indicate high-throughput sequencing counts. The sgRNA target sites are bold and 
capitalized. 
 
  In contrast, genomic off-target DNA cleavage was observed for wild-type Cas9 at all 11 
sites assayed.  Using the detection limit of the assay as an upper bound for off-target fCas9 
activity, we calculated that fCas9 has a much lower off-target modification rate than wild-type 
Cas9 nuclease.  At the 11 off-target sites modified by wild-type Cas9 nuclease, fCas9 resulted in 
on-target:off-target modification ratios at least 140-fold higher than that of wild-type Cas9 
(Figure 4.15a-d).   117 
 
  Consistent with previous reports,5,7,8 Cas9 nickase also induced substantially fewer off-
target modification events (1/11 off-target sites modified at a detectable rate) compared to wild-
type Cas9.  An initial high-throughput sequencing assay revealed significant (P value < 10-3, 
Fisher’s Exact Test) modification induced by Cas9 nickases in 0.024% of sequences at VEGF 
off-target site 1.  This genomic off-target site was not modified by fCas9 despite similar VEGF 
on-target modification efficiencies of 12.3% for Cas9 nickase and 10.4% for fCas9 (Figure 
4.15c and Appendix C).   Because Cas9 nickase-induced modification levels were within an 
order of magnitude of the limit of detection and fCas9 modification levels were undetected, we 
repeated the experiment with a larger input DNA samples and a greater number of sequence 
reads (150 versus 600 ng genomic DNA and > 8 x 105 versus > 23 x 105 reads for the initial and 
second trial, respectively) to detect off-target cleavage at this site by Cas9 nickase or fCas9.   
From this deeper interrogation, we observed Cas9 nickase and fCas9 to both significantly modify 
(P value < 10-5, Fisher’s Exact Test) VEGF off-target site 1 (Figure 4.15d and Appendix C).  
For both experiments interrogating the modification rates at VEGF off-target site 1, fCas9 
exhibited a greater on-target:off-target DNA modification ratio than that of Cas9 nickase (> 
5,150 and 1,650 for fCas9, versus 510 and 1,230 for Cas9 nickase, Figure 4.15d). 
On either side of VEGF off-target site 1 there exist no other sites with six or fewer 
mutations from either of the two half-sites of the VEGF on-target sequence.  We speculate that 
the first 11 bases of one sgRNA (V2) might hybridize to the single-stranded DNA freed by 
canonical Cas9:sgRNA binding within VEGF off-target site 1 (Figure 4.10).  Through this 
sgRNA:DNA hybridization it is possible that a second Cas9 nickase or fCas9 could be recruited 
to modify this off-target site at a very rare, but detectable frequency.  Judicious sgRNA pair 
design could eliminate this potential mode of off-target DNA cleavage, as VEGF off-target site 1 118 
 
is highly unusual in its ability to form 11 consecutive potential base pairs with the second 
sgRNA of a pair.  In general, fCas9 was unable to modify the genomic off-target sites tested 
because of the absence of any adjacent second binding site required to dimerize and induce 
cleavage by the FokI nuclease domain. 
Discussion 
The optimized FokI-dCas9 fusion architecture developed in this work modified all 11 
genomic loci targeted with gRNA spaced ~15 bp or ~25 bp apart, demonstrating the generality of 
using fCas9 to induce genomic modification in human cells, although modification with fCas9 
was less efficient than with wild-type Cas9.  The use of fCas9 is straightforward, requiring only 
that PAM sequences be present with an appropriate spacing and orientation, and using the same 
sgRNAs as wild-type Cas9 or Cas9 nickases.  The observed low off-target:on-target modification 
ratios of fCas9, > 140-fold lower than that of wild-type Cas9, likely arises from the distinct mode 
of action of dimeric FokI, in which DNA cleavage proceeds only if two DNA sites are occupied 
simultaneously by two FokI domains at a specified distance (here, ~15 bp or ~25 bp apart) and in 
a specific half-site orientation.  The resulting unusually low off-target activity of fCas9 may 
enable applications of Cas9:sgRNA-based technologies that require a very high degree of target 
specificity, such as ex vivo or in vivo therapeutic modification of human cells.   This work also 
provides a foundation for future studies to characterize in greater detail and further improve the 
DNA cleavage activity and specificity of fCas9 in vitro and in vivo.  For example, the use of 
recently described orthogonal Cas9 homologs28 coupled with obligate heterodimeric FokI 
variants30 may offer additional specificity gains. 
Methods 119 
 
Oligonucleotides and PCR 
  All oligonucleotides were purchased from Integrated DNA Technologies (IDT).  
Oligonucleotide sequences are listed in Supplementary Notes.  PCR was performed with 0.4 µL 
of 2 U/µL Phusion Hot Start Flex DNA polymerase (NEB) in 50 µL with 1x HF Buffer, 0.2 mM 
dNTP mix (0.2 mM dATP, 0.2 mM dCTP, 0.2 mM dGTP, 0.2 mM dTTP) (NEB), 0.5 µM of 
each primer and a program of: 98 ˚C, 1 min; 35 cycles of [98 ˚C, 15 s; 65 ˚C, 15 s; 72 ˚C, 30 s] 
unless otherwise noted.  
Construction of FokI-dCas9, Cas9 Nickase and sgRNA Expression Plasmids 
  The human codon-optimized streptococcus pyogenes Cas9 nuclease with NLS and 
3xFLAG tag (Addgene plasmid 43861)2 was used as the wild-type Cas9 expression plasmid.  
PCR products of wild-type Cas9 expression plasmid were assembled with Gibson Assembly 
Cloning Kit (New England Biolabs) to construct Cas9 and FokI-dCas9 variants.  Expression 
plasmids encoding a single sgRNA construct (sgRNA G1 through G13) were cloned as 
previously described.2  Briefly, sgRNA oligonucleotides containing the 20-bp protospacer target 
sequence were annealed and the resulting 4-bp overhangs were ligated into BsmBI-digested 
sgRNA expression plasmid.  For all cloning, 1 µl of ligation or assembly reaction was 
transformed into Mach1 chemically competent cells (Life Technologies).  FokI-dCas9 
expression plasmids will be available from Addgene. 
Modification of Genomic GFP 
  HEK293-GFP stable cells (GenTarget) were used as a cell line constitutively expressing 
an Emerald GFP gene (GFP) integrated on the genome.  Cells were maintained in Dulbecco's 
modified Eagle medium (DMEM, Life Technologies) supplemented with 10% (vol/vol) fetal 
bovine serum (FBS, Life Technologies) and penicillin/streptomycin (1x, Amresco).  5 × 120 
 
104 HEK293-GFP cells were plated on 48-well collagen coated Biocoat plates (Becton 
Dickinson).  One day following plating, cells at ~75% confluence were transfected with 
Lipofecatmine 2000 (Life Technologies) according to the manufacturer’s protocol.  Briefly, 1.5 
µL of Lipofecatmine 2000 was used to transfect 950 ng of total plasmid (Cas9 expression 
plasmid plus sgRNA expression plasmids).  700 ng of Cas9 expression plasmid, 125 ng of one 
sgRNA expression plasmid and 125 ng of the paired sgRNA expression plasmid with the pairs of 
targeted sgRNAs listed in Figure 4.4.  Separate wells were transfected with 1 µg of a near-
infrared iRFP670 (Addgene plasmid 45457)31 as a transfection control.  3.5 days following 
transfection, cells were trypsinized and resuspended in DMEM supplemented with 10% FBS and 
analyzed on a C6 flow cytometer (Accuri) with a 488 nm laser excitation and 520 nm filter with 
a 20 nm band pass.  For each sample, transfections and flow cytometry measurements were 
performed once. 
T7 Endonuclease I Surveyor Assays of Genomic Modifications 
  HEK293-GFP stable cells were transfected with Cas9 expression and sgRNA expression 
plasmids as described above.  A single plasmid encoding two separate sgRNAs was transfected.  
For experiments titrating the total amount of expression plasmids (Cas9 expression + sgRNA 
expression plasmid), 700/250, 350/125, 175/62.5, 88/31 ng of Cas9 expression plasmid/ng of 
sgRNA expression plasmid were combined with inert carrier plasmid, pUC19 (NEB), as 
necessary to reach a total of 950 ng transfected plasmid DNA.  
Genomic DNA was isolated from cells 2 days after transfection using a genomic DNA isolation 
kit, DNAdvance Kit (Agencourt).  Briefly, cells in a 48-well plate were incubated with 40 µL of 
tryspin for 5 min at 37 °C. 160 uL of DNAdvance lysis solution was added and the solution 
incubated for 2 hr at 55 °C and the subsequent steps in the Agencourt DNAdvance kit protocol 121 
 
were followed.  40 ng of isolated genomic DNA was used as template to PCR amplify the 
targeted genomic loci with flanking Surveyor primer pairs. PCR products were purified with a 
QIAquick PCR Purification Kit (Qiagen) and quantified with Quant-iT™ PicoGreen ® dsDNA 
Kit (Life Technologies).  250ng of purified PCR DNA was combined with 2 µL of NEBuffer 2 
(NEB) in a total volume of 19 µL and denatured then re-annealed with thermocycling at 95 ˚C 
for 5 min, 95 to 85 ˚C at 2 ˚C/s; 85 to 20 ˚C at 0.2 ˚C/s.   The re-annealed DNA was incubated 
with 1 µl of T7 Endonuclease I (10 U/µl, NEB) at 37 °C for 15 min.  10 µL of 50% glycerol was 
added to the T7 Endonuclease reaction and 12 µL was analyzed on a 5% TBE 18-well Criterion 
PAGE gel (Bio-Rad) electrophoresed for 30 min at 150 V, then stained with 1x SYBR Gold 
(Life Technologies) for 30 min.  Cas9-induced cleavage bands and the uncleaved band were 
visualized on an AlphaImager HP (Alpha Innotech) and quantified using ImageJ software.32  The 
peak intensities of the cleaved bands were divided by the total intensity of all bands (uncleaved + 
cleaved bands) to determine the fraction cleaved which was used to estimate gene modification 
levels as previously described.33  For each sample, transfections and subsequent modification 
measurements were performed in triplicate on different days. 
High-throughput Sequencing of Genomic Modifications 
  HEK293-GFP stable cells were transfected with Cas9 expression and sgRNA expression 
plasmids, 700 ng of Cas9 expression plasmid plus 250 ng of a single plasmid expression a pair of 
sgRNAs were transfected (high levels) and for just Cas9 nuclease, 88 ng of Cas9 expression 
plasmid plus 31 ng of a single plasmid expression a pair of sgRNAs were transfected (low 
levels).  Genomic DNA was isolated as above and pooled from three biological replicates.  150 
ng or 600 ng of pooled genomic DNA was used as template to amplify by PCR the on-target and 
off-target genomic sites with flanking HTS primer pairs.  Relative amounts of crude PCR 122 
 
products were quantified by gel electrophoresis and samples treated with different sgRNA pairs 
or Cas9 nuclease types were separately pooled in equimolar concentrations before purification 
with the QIAquick PCR Purification Kit (Qiagen). ~500 ng of pooled DNA was run a 5% TBE 
18-well Criterion PAGE gel (BioRad) for 30 min at 200 V and DNAs of length ~125 bp to ~300 
bp were isolated and purified by QIAquick PCR Purification Kit (Qiagen).  Purified DNA was 
PCR amplified with primers containing sequencing adaptors, purified and sequenced on a MiSeq 
high-throughput DNA sequencer (Illumina) as described previously.1  
Sensitivity limit of off-target cleavage assays 
The sensitivity of the high-throughput sequencing method for detecting genomic off-
target cleavage is limited by the amount genomic DNA (gDNA) input into the PCR amplification 
of each genomic target site.  A 1 ng sample of human gDNA represents only ~330 unique 
genomes, and thus only ~330 unique copies of each genomic site are present.  PCR amplification 
for each genomic target was performed on a total of 150 ng, 300 ng, or 600 ng of input gDNA, 
which provides amplicons derived from at most 50,000, 100,000 or 200,000 unique gDNA 
copies, respectively.  Therefore, the high-throughput sequencing assay cannot detect rare genome 
modification events that occur at a frequency of less than 1 in 50,000 (0.002%), less than 1 in 
100,000 (0.001%), or less than 1 in 200,000 (0.0005%), respectively. 
Data Analysis  
  Illumina sequencing reads were filtered and parsed with scripts written in Unix Bash as 
outlined in Appendix D.  DNA sequences will be deposited in NCBI’s Sequencing Reads 
Archive (SRA).  Sample sizes for sequencing experiments were maximized (within practical 
experimental considerations) to ensure greatest power to detect effects.  Statistical analyses for 123 
 
Cas9-modified genomic sites in Appendix C were performed as previously described34 with 
multiple comparison correction using the Bonferroni method.  
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Appendix A 
a 
Spacer length (b) 
 
Number of paired sgRNA sites 
in orientation A 
Number of paired sgRNA sites 
in orientation B 
-8  6874293  NC 
-7  6785996  NC 
-6  6984064  NC 
-5  7023260  NC 
-4  6487302  NC 
-3  6401348  NC 
-2  6981383  NC 
-1  7230098  NC 
0  7055143  NC 
1  6598582  NC 
2  6877046  NC 
3  6971447  NC 
4  6505614  5542549 
5  6098107  5663458 
6  6254974  6819289 
7  6680118  6061225 
8  7687598  5702252 
9  6755736  7306646 
10  6544849  6387485 
11  6918186  6172852 
12  6241723  5799496 
13  6233385  7092283 
14  6298717  7882433 
15  6181422  7472725 
16  6266909  6294684 
17  6647352  6825904 
18  6103603  6973590 
19  5896092  6349456 
20  6000683  5835825 
21  5858015  6056352 
22  6116108  6531913 
23  5991254  6941816 
24  6114969  6572849 
25  6135119  5671641 
 
b 
Cas9 variant  Preferred spacer lengths (bp)  Total sites 
fCas9   13 to 19, or 22 to 29, in orientation A  92354891 
Cas9 nickase 
-8 to 100 in orientation A 
4 to 42 in orientation B  953048977 
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Appendix A (continued) 
Appendix A. Paired sgRNA target site abundances for fCas9 and Cas9 nickase in the human 
genome.  (a) Column 2 shows the number of sites in the human genome with paired sgRNA binding sites 
in orientation A allowing for a spacer length from -8 bp to 25 bp (column 1) between the two sgRNA 
binding sites. sgRNA binding sites in orientation A have the NGG PAM sequences distal from the spacer 
sequence (CCNN20-spacer-N20NGG).   Column 3 shows the number of sites in the human genome with 
paired sgRNA binding sites in orientation B allowing for a spacer length from 4 to 25 bp (column 1) 
between the two sgRNA binding sites.  sgRNA binding sites in orientation B have the NGG PAM 
sequences adjacent to the spacer sequence (N20NGG spacer CCNN20) .  NC indicates the number of sites 
in the human genome was not calculated.  Negative spacer lengths refer to target sgRNA binding sites 
that overlap by the indicated number of base pairs. (b) Sum of the number of paired sgRNA binding sites 
in orientation A with spacer lengths of 13 to 19 bp, or 22 to 29 bp, the spacer preference of fCas9 (Figure 
4.12).  Sum of the number of paired sgRNA binding sites with spacer lengths of -8 bp to 100 bp in 
orientation A, or 4 to 42 bp in orientation B, the spacer preference of Cas9 nickases (4 to 42 bp in 
orientation B is based on Figures 4.9 and 4.14, and -8 bp to 100 bp in orientation A is based on previous 
reports).   
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Appendix B 
 
Genomic target site 
EMX_On  GAGTCCGAGCAGAAGAAGAAGGG 
EMX_Off1  GAGgCCGAGCAGAAGAAagACGG 
EMX_Off2  GAGTCCtAGCAGgAGAAGAAGaG 
EMX_Off3  GAGTCtaAGCAGAAGAAGAAGaG 
EMX_Off4  GAGTtaGAGCAGAAGAAGAAAGG  
   
VEG_On  GGGTGGGGGGAGTTTGCTCCTGG 
VEG_Off1  GGaTGGaGGGAGTTTGCTCCTGG 
VEG_Off2  GGGaGGGtGGAGTTTGCTCCTGG 
VEG_Off3  cGGgGGaGGGAGTTTGCTCCTGG 
VEG_Off4  GGGgaGGGGaAGTTTGCTCCTGG 
   
CLT2_On  GCAGATGTAGTGTTTCCACAGGG 
CLT2_Off1  aCAaATGTAGTaTTTCCACAGGG 
CLT2_Off2  cCAGATGTAGTaTTcCCACAGGG 
CLT2_Off3  ctAGATGaAGTGcTTCCACATGG 
 
Appendix B.  Known off-target substrates of Cas9 target sites in EMX, VEGF, and CLTA.  List of 
genomic on-target and off-targets sites of the EMX, VEGF, and CLTA are shown with mutations from 
on-target in lower case and red.  PAMs are shown in blue. 
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Appendix C 
a 
Nuclease type:  wt Cas9  wt Cas9 
Cas9  
nickase  fCas9  wt Cas9 
Cas9  
nickase  fCas9 
sgRNA pair target:  CLTA  CLTA  CLTA  CLTA  GFP  GFP  GFP 
Total expression 
plasmids (ng):  1000  125  1000  1000  1000  1000  1000 
CLTA Sites 
              CLT2_On 
              Indels  3528  1423  3400  575  3  13  5 
Total  10000  10000  10000  10000  10000  10000  10000 
Modified (%)  35.280  14.230  34.000  5.750  0.030  0.130  0.050 
P-value   <1.0E-300  <1.0E-300  <1.0E-300  1.4E-163 
      On:off specificity  1  1 
 
1 
     
                CLT2_Off1 
              Indels  316  44  2  2  1  3  3 
Total  60620  64755  71537  63079  93883  91306  82055 
Modified (%)  0.521  0.068  0.003  0.003  <0.002  0.003  0.004 
P-value   1.3E-126  2.1E-16       
      On:off specificity  68  209 
 
>2850 
     
                CLT2_Off2 
              Indels  11  5  3  1  1  1  2 
Total  72596  51093  59632  35541  69114  64412  39978 
Modified (%)  0.015  0.010  0.005  0.003  <0.002  <0.002  0.005 
P-value   6.5E-03          
      On:off specificity  2328  1454 
 
>2850 
     
                CLT2_Off3 
              Indels  11  10  0  0  1  1  1 
Total  52382  44212  54072  48668  55670  58707  54341 
Modified (%)  0.021  0.023  <0.002  <0.002  <0.002  <0.002  <0.002 
P-value   2.7E-03  3.5E-03       
      On:off specificity  1680  629    >2850       
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Appendix C (continued) 
B  
Nuclease type:  wt Cas9  wt Cas9 
Cas9  
nickase  fCas9  wt Cas9 
Cas9  
nickase  fCas9 
sgRNA pair:  EMX  EMX  EMX  EMX  GFP  GFP  GFP 
Total expression 
plasmids (ng):  1000  125  1000  1000  1000  1000  1000 
EMX Site 
              EMX_On 
              Indels  5111  2683  2267  522  0  0  2 
Total  10000  10000  10000  10000  10000  10000  10000 
Modified (%)  51.110  26.830  22.670  5.220  <0.002  <0.002  0.020 
P-value   <1.0E-300  <1.0E-300  <1.0E-300  1.0E-154 
      On:off specificity  1  1  1  1 
     
                EMX_Off1 
              Indels  386  122  7  1  4  9  7 
Total  109787  83420  124564  88424  102817  90020  96526 
Modified (%)  0.352  0.146  0.006  <0.002  0.004  0.010  0.007 
P-value   1.3E-103  2.8E-37       
      On:off specificity  145  183  >11222  >2584 
     
                EMX_Off2 
              Indels  74  58  3  6  3  0  4 
Total  98568  94108  105747  78871  81717  79469  79193 
Modified (%)  0.075  0.062  0.003  0.008  0.004  <0.002  0.005 
P-value   3.2E-16  1.4E-12       
      On:off specificity  681  435  >11222  >2584 
     
                EMX_Off3 
              Indels  736  178  20  14  12  11  17 
Total  72888  65139  82348  59593  74341  73408  75080 
Modified (%)  1.010  0.273  0.024  0.023  0.016  0.015  0.023 
P-value   2.5E-202  3.1E-44       
      On:off specificity  51  98  >11222  >2584 
     
                EMX_Off4 
              Indels  4149  620  3  3  6  7  5 
Total  107537  91695  91368  91605  111736  119643  128088 
Modified (%)  3.858  0.676  0.003  0.003  0.005  0.006  0.004 
P-value   <1.0E-300  1.9E-202       
      On:off specificity  13  40  >11222  >2584       132 
 
Appendix C (continued) 
c 
Nuclease type:  wt Cas9  wt Cas9 
Cas9  
nickase  fCas9  wt Cas9 
Cas9  
nickase  fCas9 
sgRNA pair:  VEGF  VEGF  VEGF  VEGF  GFP  GFP  GFP 
Total expression 
plasmids (ng):  1000  125  1000  1000  1000  1000  1000 
VEGF Sites 
              VEG_On 
              Indels  5253  2454  1230  1041  8  0  1 
Total  10000  10000  10000  10000  10000  10000  10000 
Modified (%)  52.530  24.540  12.300  10.410  0.080  <0.002  0.010 
P-value   <1.0E-300  <1.0E-300  <1.0E-300  6.6E-286 
      On:off specificity  1  1  1  1 
     
                VEG_Off1 
              Indels  2950  603  22  0  0  4  1 
Total  82198  71163  90434  77557  74765  79738  74109 
Modified (%)  3.589  0.847  0.024  <0.002  <0.002  0.005  <0.002 
P-value   <1.0E-300  3.2E-188  2.5E-06    
      On:off specificity  15  29  506  >5150 
     
                VEG_Off2 
              Indels  863  72  3  3  0  2  1 
Total  102501  49836  119702  65107  54247  65753  61556 
Modified (%)  0.842  0.144  0.003  0.005  <0.002  0.003  <0.002 
P-value   3.5E-159  9.6E-24       
      On:off specificity  62  170  >6090  >5150 
     
                VEG_Off3 
              Indels  260  33  3  2  3  1  0 
Total  91277  83124  90063  84385  62126  68165  69811 
Modified (%)  0.285  0.040  0.003  0.002  0.005  <0.002  <0.002 
P-value   6.8E-54  1.0E-05       
      On:off specificity  184  618  >6090  >5150 
     
                VEG_Off4 
              Indels  1305  149  3  2  3  2  4 
Total  59827  41203  65964  57828  60906  61219  62162 
Modified (%)  2.181  0.362  0.005  0.003  0.005  0.003  0.006 
P-value   <1.0E-300  2.7E-54       
      On:off specificity  24  68  >6090  >5150       133 
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d 
Nuclease type: 
Cas9  
nickase  fCas9 
Cas9  
nickase  fCas9 
sgRNA pair:  VEGF  VEGF  GFP  GFP 
Total expression 
plasmids (ng):  1000  1000  1000  1000 
VEGF Sites 
        VEG_On 
        Indels  2717  2122  10  13 
Total  10000  10000  10000  10000 
Modified (%)  27.170  21.220  0.100  0.130 
P-value   <1.0E-300  <1.0E-300 
    On:off specificity  1  1 
   
          VEG_Off1 
        Indels  67  30  3  2 
Total  302573  233567  204454  190240 
Modified (%)  0.022  0.013 
    P-value   5.9E-12  2.5E-06 
    On:off specificity  1227  1652 
     
Appendix C.  Cellular modification induced by wild-type Cas9, Cas9 nickase, and fCas9 at on-
target and off-target genomic sites.  (a) Results from sequencing CLTA on-target and previously 
reported genomic off-target sites amplified from 150 ng genomic DNA isolated from human cells treated 
with a plasmid expressing either wild-type Cas9, Cas9 nickase, or fCas9 and a single plasmid expressing 
two sgRNAs targeting the CLTA on-target site (sgRNA C3 and sgRNA C4).  As a negative control, 
transfection and sequencing were performed as above, but using two sgRNAs targeting the GFP gene on-
target site (sgRNA G1, G2 or G3 and sgRNA G4, G5, G6 or G7.  Indels: the number of observed 
sequences containing insertions or deletions consistent with any of the three Cas9 nuclease-induced 
cleavage.  Total: total number of sequence counts while only the first 10,000 sequences were analyzed for 
the on-target site sequences.  Modified: number of indels divided by total number of sequences as 
percentages.  Upper limits of potential modification were calculated for sites with no observed indels by 
assuming there is less than one indel then dividing by the total sequence count to arrive at an upper limit 
modification percentage, or taking the theoretical limit of detection (1/49,500), whichever value was 
larger.  P-values: For wild-type Cas9 nuclease, Cas9 nickase or fCas9 nuclease, P-values were calculated 
as previously reported18 using a two-sided Fisher’s exact test between each sample treated with two 
sgRNAs targeting the CLTA on-target site and the control sample treated with two sgRNAs targeting the 
GFP on-target site.  P-values of < 0.0045 were considered significant and shown based on conservative 
multiple comparison correction using the Bonferroni method.  On:off specificity is the ratio of on-target 
to off-target genomic modification frequency for each site.  (b) Experimental and analytic methods as in 
(a) applied to EMX target sites using a single plasmid expressing two sgRNAs targeting the EMX on- 134 
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target site (sgRNA E1 and sgRNA E2).  (c) Experimental and analytic methods as in (a) applied to VEGF 
target sites using a single plasmid expressing two sgRNAs targeting the VEGF on-target site (sgRNA V1 
and sgRNA v2).  (d) Experimental and analytic methods as in (a) applied to VEGF on-target and VEGF 
off-target site 1 amplified from 600 ng genomic DNA to increase detection sensitivity to 1/198,000. 
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Appendix D 
Computational Search for Potential Target Sites 
1) The Patmatch program4 was used to search the human genome (GRCh37/hg19 build) for 
pattern sequences corresponding to Cas9 binding sites (CCN N20 spacer N20NGG for Orientation 
A and N20NGG spacer CCN N20 for Orientation B) 
 
Identification of Indels in Sequences of Genomic Sites 
1) Sequence reads were initially filtered removing reads of less than 50 bases and removing reads 
with greater than 10% of the Illumina base scores not being B-J: 
Example SeqA-1stread: 
TTCTGAGGGCTGCTACCTGTACATCTGCACAAGATTGCCTTTACTCCATGCCTTTCTTCTTCTG
CTCTAACTCTGACAATCTGTCTTGCCATGCCATAAGCCCCTATTCTTTCTGTAACCCCAAGAT
GGTATAAAAGCATCAATGATTGGGC 
Example SeqA-2stread: 
AAAACTCAAAGAAATGCCCAATCATTGATGCTTTTATACCATCTTGGGGTTACAGAAAGAAT
AGGGGCTTATGGCATGGCAAGACAGATTGTCAGAGTTAGAGCAGAAGAAGAAAGGCATGG
AGTAAAGGCAATCTTGTGCAGATGTACAGGTAA 
 
2) Find the first 20 bases four bases from the start of the reverse complement of SeqA-2ndread 
in SeqA-1stread allowing for 1 mismatch: 
Reverse complement of SeqA-2ndread: 
TTACCTGTACATCTGCACAAGATTGCCTTTACTCCATGCCTTTCTTCTTCTGCTCTAACTCTG
ACAATCTGTCTTGCCATGCCATAAGCCCCTATTCTTTCTGTAACCCCAAGATGGTATAAAAGC
ATCAATGATTGGGCATTTCTTTGAGTTTT 
  Position in SeqA-1stread 
TTCTGAGGGCTGCTACCTGTACATCTGCACAAGATTGCCTTTACTCCATGCCTTTCTTCTTC
TGCTCTAACTCTGACAATCTGTCTTGCCATGCCATAAGCCCCTATTCTTTCTGTAACCCCAAG
ATGGTATAAAAGCATCAATGATTGGGC 
 
3)  Align and then combine sequences, removing any sequence with greater than 5% mismatches 
in the simple base pair alignment: 
Combination of SeqA-1stread and SeqA-2ndread: 136 
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TTCTGAGGGCTGCTACCTGTACATCTGCACAAGATTGCCTTTACTCCATGCCTTTCTTCTTC
TGCTCTAACTCTGACAATCTGTCTTGCCATGCCATAAGCCCCTATTCTTTCTGTAACCCCAAG
ATGGTATAAAAGCATCAATGATTGGGCATTTCTTTGAGTTTT 
 
4)  To identify the target site the flanking genomic sequences were searched for with the 
Patmatch program4 allowing for varying amounts of bases from 1 to 300 between the flanking 
genomic sequences:  
Target Site  Downstream genomic sequence  Upstream genomic sequence 
EMX_On  GGCCTGCTTCGTGGCAATGC  ACCTGGGCCAGGGAGGGAGG 
EMX_Off1  CTCACTTAGACTTTCTCTCC  CTCGGAGTCTAGCTCCTGCA 
EMX_Off2  TGGCCCCAGTCTCTCTTCTA  CAGCCTCTGAACAGCTCCCG 
EMX_Off3  TGACTTGGCCTTTGTAGGAA  GAGGCTACTGAAACATAAGT 
EMX_Off4  TGCTACCTGTACATCTGCAC  CATCAATGATTGGGCATTTC 
VEG_On  ACTCCAGTCCCAAATATGTA  ACTAGGGGGCGCTCGGCCAC 
VEG_Off1  CTGAGTCAACTGTAAGCATT  GGCCAGGTGCAGTGATTCAT 
VEG_Off2  TCGTGTCATCTTGTTTGTGC  GGCAGAGCCCAGCGGACACT 
VEG_Off3  CAAGGTGAGCCTGGGTCTGT  ATCACTGCCCAAGAAGTGCA 
VEG_Off4  TTGTAGGATGTTTAGCAGCA  ACTTGCTCTCTTTAGAGAAC 
CLT2_On  CTCAAGCAGGCCCCGCTGGT  TTTTGGACCAAACCTTTTTG 
CLT2_Off1  TGAGGTTATTTGTCCATTGT  TAAGGGGAGTATTTACACCA 
CLT2_Off2  TCAAGAGCAGAAAATGTGAC  CTTGCAGGGACCTTCTGATT 
CLT2_Off3  TGTGTGTAGGACTAAACTCT  GATAGCAGTATGACCTTGGG 
SiteA_On  GCTCTGCCACCACAAGCTTTGGGCA  CCCTTTGCATCCATTCCCCCTACCA 
SiteA_Off1  GGAGATGAACCAGCCTGCAGTCAAG  ACTGATCTATGCCTGTGCCTTTGTG 
SiteA_Off2  CCCAGTCCCTATCACAAAAAAAGAT  ACATTGATCATCATGGCCACTGGAT 
SiteA_Off3  TCCTGATGCCAGCACTCAGTGCCTG  AAGAGCACCAAGTACAGTCTGTGGC 
SiteB_On  TTCCCAAACTGCTGGGATTACAGGC  TGCTACTGTGTACTAAGGGCATAGT 
SiteB_Off1  CTCAGCCTCTCAAAGTGCTGGGATT  TATCTCCTTCCCTTTCCTTCCCTTC 
SiteB_Off2  CTCCCAAAGTGCTGGGATTACAGGC  TTTGGTTTATAGAAACACCATTGAT 
SiteB_Off3  CTCCCAAAGTGCTGGGATTACAAGG  GAATGTTAAGTTTGTCCAGAGGCCA 
SiteB_Off4  GCCTCCCAAAGTGCTGGGATTACAG  CCAGCACTTTGGGAGGCCAAAGCGG 
SiteC_On  CCTCAGCTTCCCAAACTGCTGAGAT  GTGTGACCTTTGCTTTGGAACTGTG 
SiteC_Off1  TCTCGACCTCCCTAAGTGCTGGGAT  CTTGCAGAAGAGTGCCAGTTGTGGT 
SiteC_Off2  AATCTGCCCACCTCGGCCTCCCAAA  TACCACTTTTAAAATTTCACTTCTC 
SiteC_Off3  CTCCCAAAGTGCTGGTATTACAGGT  CTTTTGTCTTAATAATTCCTCTATT 
SiteC_Off4  CTGCCTCAGCCTCCCGAAGTGCTAG  ATAATCCCAGCACTTTGAAAGGCTG 
 
4)  Any target site sequences corresponding to the same size as the reference genomic site in the 
human genome (GRCh37/hg19 build) were considered unmodified and any sequences not the  137 
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reference size were considered potential insertions or deletions.  Sequences not the reference size 
were aligned with  
ClustalW to the reference genomic site.  Aligned sequences with more than one insertion or one 
deletion in the DNA spacer sequence in or between the two half-site sequences were considered 
indels.  Since high-throughput sequencing can result in insertions or deletions of one base pairs 
(mis-phasing) at a low but relevant rates - indels of two bp are more likely to arise from Cas9 
induced modifications. 
 